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A method was validated for the analysis of six benzodiazepines listed under Section 5A of 
the Road traffic Act. The benzodiazepines selected were diazepam, oxazepam, temazepam, 
clonazepam, lorazepam and flunitrazepam in line with ISO 17025 guidelines. The method 
can be utilised for casework analysis of blood samples in road traffic toxicology for all six 
benzodiazepines for assessing if a motorist’s blood sample is above the per se limits. In 
addition, the method was validated in line with the criteria and general guidelines stipulated 
in document FSR-C-133 and specifications for methods to use for Section 5A of the Road 
Traffic Act. The method has met all requirements detailed by FSR-C-133 including minimum 
number of calibrators, QC’s, along with validated parameters of linearity, accuracy, 
precision, percentage recovery, matrix effect and robustness. The developed method has an 
accuracy of ±10%, a %CV of ≤10%, linearity of ≥0.99 for all analytes. The LOQ was set at 
the first calibration point and the LOD was half the LOQ concentration. In all cases the LOD 
and LOQ displayed suitable ion ratio acceptance (≤10% of target) and accuracy (≤10% of 
target). The method displayed ion suppression in all analytes. The average ion suppression 
was -48%, this did not affect the methods accuracy or sensitivity as indicated by studies on 
LOD and LOQ. Further parameters tested included reproducibility with three separate 
extractions from three separate analyst on different days, in all three extractions the methods 
performance was unaffected. The analysis of all six benzodiazepines is possible, at 
concentrations typically detected in samples and cases found in road traffic incidents. 
Although a method was developed and validated for six benzodiazepines, there is scope to 
expand the method and add other less commonly detected benzodiazepines. Moreover, the 
method was validated to take into account a variety of storage conditions; room temperature, 
refrigerated and frozen and then analysed to ascertain whether the method was suitable in 
casework study where samples are not analysed on the same day. The results indicate that the 
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1.1 Origin of Benzodiazepines  
The unintentional discovery of chlorodiazepoxide represents a significant starting point in the 
history of central nervous system depressants (Gerecke, 1983). First founded by L.H 
Sternbach and L.O Randall in 1957, the compound gave rise to an array of moieties with 
similar therapeutic properties. Chlordiazepoxide (marketed as Librium) was initially accepted 
with high praise by the medical community, resulting in an exponential growth in patient 
demand and by the late 70’s it was the most prescribed drug in the world (Wick, 2013). 
However, the therapeutic merits of the chlorodiazepoxide drug came under increasing 
scrutiny as the potential for addiction and dependence was realised (Sternbach, 1979). 
With the efficacy to treat a wide array of medical conditions, benzodiazepines are a family, or 
class, of drugs that are predominantly used to treat sleeping disorders, anxiety, muscle spasms 
and epilepsy seizures (O.H. Drummer, 2001). Benzodiazepines are subdivided into different 
classes based on their activity as a depressant, sedative or hypnotic. The most widely used 
and prescribed benzodiazepine is diazepam (Valium). Other drugs of similar use but of 
different structural compounds that will also be investigated are oxazepam (Serax), 
lorazepam (Ativan), flunitrazepam (Rohypnol), clonazepam (Klonopin) and temazepam 
(Restoril). These drugs are typically controlled and only available with a valid prescription, 
however, their cost and ease of availability has made them a widely encountered drug of 
abuse. 
 
1.2 Chemical structure of BZD 
 
The core structure of a benzodiazepine consists of a bicyclic heterocyclic compound having a 
benzene nucleus fused to a seven-membered ring containing two nitrogen atoms (Qadir, 
2015). The variation in R groups attached to the general structure, allow for increased 
efficiency of GABA (gamma-aminobutyric acid), a neurotransmitter that decreases neuron 
excitation, leading to reduced propagation of nerve signals. Sternbach et al. discovered that 
the N-Oxide and the methyamino group in positions 4 and 2 respectively hindered the 
efficacy of the compound. Structural relationships between the core drug and the target 
receptor has allowed the development of drugs with higher selectivity to the target receptor 
resulting in increased potency or activity. By interchanging these groups through oxidation or 
reduction it was discovered compounds with varying degrees of potency could be formulated 
(Sternbach, 1968). 
 
Interchanging the following groups affect benzodiazepine binding sites and their intrinsic 
activity in relation to GABAA receptors. Consequently, this determines agonist, antagonist 
and inverse agonist behaviour. The agonists allosterically modulate GABA binding to the 
receptor, which in turn applies a positive cooperative effect; thus there is an increase in 
frequency of chloride channel openings (Wang, Han and Xue, 2006). This allows a greater 
flow of chloride ions into the neuron and ultimately leads to membrane hyperpolarisation and 
decreased neuron excitability. The resultant physiological effect is a reduction in brain/central 
nervous system activity and a decrease in anxiety (Sorensen et al., 2017). 
 
In position 1, polarity is the most important concept when deciding on the constituent; the 
size of the substituent is important (Wang, Han and Xue, 2006). Only the methyl group 
increases binding potential and any larger substituent will decrease it. At position 2 a 
carbonyl group is present which is critical for the pharmacological activity; this functional 
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group acts as the receptor binding motif via histidine residue proton donation (So and 
Karplus, 1996). One of the few chemical substitutions that can effectively replace this 
carbonyl group and retain receptor activity is the addition of a halogen in position 2. This 
substitution results in a significant increase in drug potency; conversely a reduction in affinity 
for the GABA receptor occurs when a halogen is substituted into position 4. Groups at 
position 3 are responsible for the pharmacokinetic activity of the drug. For position 3 any 
substituent bigger than a methyl or hydroxyl group (such as ethyl or carboxyl) will contribute 
to a loss of efficacy. In addition, highly polar groups are directly conjugated resulting in 
direct excretion of the drug or metabolite thereby reducing the duration of action. Positions 4 
and 5 require the unsaturated double bond for activity and any saturation decreases activity. 
(Maddalena, 1995). By contrast, position 5 requires an aromatic ring for optimal action; such 
as the phenyl group present in diazepam. Activity can be increased by substitution on the 
phenyl group with an electronegative compound, such as fluorine. However, stoichiometric 
positioning is also a significant factor in determining drug potency, as the group has to be 
substituted in the ortho position; as para substitution will decrease efficacy. For position 7 
research has shown that an electro-negative group is integral for optimal activity and cannot 
be compromised. The general rule of the thumb is the higher the electronegativity and 
lipophilicity of the group attached at position 7, the more potent the drug will be; due to 
increased affinity of the ligand for the binding site (Wang, Han and Xue, 2006). Another 
avenue of variation is the introduction of additional rings, primarily attached to the diazepine 
ring (Gerecke, 1983). Research undergone has shown positions 6,8 and 9 should not be 





























Figure 1. An illustration of the classic benzodiazepine with its assigned numbering 




















































Figure 2. Synthesis of 1,5-benzodiazepines using H-MCM-22 zeolite 
catalysts at room temperature. (Majid, Khanday and Tomar, 2012) 
 
Figure 3. Reaction mechanism of the synthesis of 1,5-benzodiazepines using H-MCM-22 
catalyst at room temperature (Shobha et al., 2010). 
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1.2 Pharmacology of Benzodiazepines  
 
Benzodiazepines are often categorised on the elimination half-life of the drug based on their 
pharmacokinetic parameters. Categories are approximate, since half-life may vary from 
individual to individual based on height, weight and underlying health conditions. There may 
be some overlap where medium acting benzodiazepines have longer durations due to active 
metabolites that are formed from the pro-drug (Greenblatt, Shader, Divoll and Harmatz, 
1981). The drugs in question on this research project are all solely medium half-life and long 
half-life. In addition, all drugs in this project are outlined in Section 5A of the road traffic act. 
Although this is not an exhaustive list of benzodiazepines, all those included are most 
commonly found in UK motorists. 
 
Table 1: List of benzodiazepines, their therapeutic use, range of half-life and average daily 
dose (Baselt, 2020). 
Name of drug Usage: Anxiolytic or 
Hypnotic 

































Medium-acting benzodiazepines have a net biochemical half-life of 8-24 hours (Moffat, 
Osselton, Widdop and Watts, 2011). Active metabolites are less common and 
pharmacological activity is typically derived from the parent compound alone. Their shorter 
half-life and faster clearance results in drug accumulation in the body being less prevalent. 
During multiple dose treatment a steady state condition is quickly attained where the 
maximum desired effect of the drug is achieved without the effect of over sedation with 
hypnotics due to the build-up and residual effects of prior doses (Greenblatt et al., 1979). 
 
Long-acting benzodiazepines have a half-life of 24 hours or longer (Moffat, Osselton, 
Widdop and Watts, 2011). They commomly have a rapid onset of action and are clinically 
effective over a short term (Furukawa et al., 2002); 2-4 weeks (Kennedy and O’Riordan, 
2019). This is due to either the parent compound or one of the pharmacologically active 
metabolites. A direct result is drug accumulation when patients are taking multiple doses 
and accumulation may occur at different rates based on half-life and how fast drugs are 
cleared from the body. Accumulation has both advantages and disadvantages, where a 
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single dose may be advantageous for those suffering from anxiety and insomnia. In addition, 
a missed dosage may not have such an adverse effect where the pre-medicated symptoms 
arise (Greenblatt, Shader, Divoll and Harmatz, 1981). However, longer acting 
benzodiazepines may have the effect of over sedation and anterograde amnesia, which are 
α1 mediated (van Rijnsoever, 2004). 
 
Although all benzodiazepines work in a similar way and have almost identical functionality, 
it is noteworthy that potency differs hugely. As a result, the potency of equivalent doses 
between different benzodiazepines can vary as high as 20-fold. This difference in potency 
should be taken into consideration when switching between different benzodiazepines. For 
example, when switching from lorazepam to diazepam to reduce withdrawal effects 
(Ashton, 2002). 
 
Depending on the dosage, medical condition and underlying health complications, the route 
of administration of benzodiazepines can vary. Predominantly, the drug is taken orally as a 
whole tablet or capsule with the active ingredient inside. In medical settings the drug can be 
taken intravenous, intramuscular or in rectal gel form. However, it can also be dissolved in 
drinks before drinking or is crushed up into a fine powder before snorting it through the nasal 
cavity. The latter route is not used medically but is more common among recreational users 
as it achieves the user desired effect rapidly.  
 
Once administered orally benzodiazepines are readily absorbed into the circulatory system. 
On the contrary, when administered intramuscularly, uptake and absorption of some drugs 
are often erratic and pain at the injection site may occur. Benzodiazepines and their 
metabolites are highly protein bound and have a highly lipophilic nature exhibiting a large 
volume of distribution (0.7-21/Kg) (Nilsson, 1991). The more lipophilic a benzodiazepine, the 
faster the rate of absorption and thus a faster clinical onset. Most benzodiazepines are 
metabolised via oxidation by the cytochrome P450(CYP)3A (Phase 1) (Griffin et al., 2013). 
Active metabolites are further metabolised via polymorphic cytochrome CYP3A and 
CYP2C19 isoforms (Kim et al., 2017). During (Phase 2) active metabolites are metabolised to 
glucuronide conjugates (Kim et al., 2017) and almost entirely excreted via urine (Griffin et 
al., 2013). The cytochrome P450 and its enzymes act as inhibitors or inducers which in turn 
affect its metabolism and clearance from the body. Although not completely characterised, 
studies suggest inducers increase enzyme activity by increasing enzyme synthesis, thereby 
increasing metabolism and clearance time. However, inhibitors will directly inhibit the 
activity of cytochrome P450 (Meyer, 2012) resulting in slower metabolism and clearance and 
the possibility of drug accumulation as represented by longer-acting benzodiazepines. 
Benzodiazepines produce their effect by binding to the central benzodiazepine receptors 
which are situated at the post and presynaptic membranes (Burt and Kamatchi, 1991). GABA 
is the most common of neurotransmitters found in the CNS and is present in high 
concentrations in the cortex and limbic region (Wu and Sun, 2014, Xu et al., 2011); 
responsible for regulating memory, emotion and stimulation. GABA has 3 different sub-units 
assigned letters A-C; GABAA is the binding motif that interacts with benzodiazepines. This 
can be further broken down into receptor complexes containing 2 α subunits, 2 β subunits and 
1 γ subunit. Each α subunit contains histidine residues H101, H101, H126, and H105, 
commonly denoted as 1, 2, 3 and 5 respectively (Griffin et al., 2013). These residues have a 
high affinity for benzodiazepines which potentiate the binding and subsequent 
pharmacological effects. Each GABAA receptor has two binding sites. Benzodiazepine 
binding sites can be located at the interface between α and β subunits where they join 
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together and create a pocket (Kelly et al., 2002). GABAA receptors act as a ligand gated ion 
channel. In the mammalian central nervous system, GABA works as a key inhibitory 
neurotransmitter in opposition to glutamate, the excitatory neurotransmitter (Gordon et al., 
1990). When activated GABA is able to control the Cl- concentration in its pores and 
augments chloride currents. Benzodiazepines increase GABA responses by lengthening the 
average channel opening time by a factor of five, while no change is made in the single 
channel current amplitude (Charles et al., 1991). Consequently, chloride ions are able to flow 
through the GABA channel for a longer period of time after being exposed to 
benzodiazepines or barbiturates. 
 
On the principle of α, β and γ subunits having different isoforms indicated with a numbering 
system akin to their different properties such as affinity for different benzodiazepines; 
benzodiazepine receptors are also categorised numerically. The BZ1 receptor contains α1 
isoforms (SIEGHART, 1992). Due to this, benzodiazepines binding to the BZ1 receptor 
elicits effects of sedation and amnesia. The majority (60%) of GABAA  receptors contain the 
BZ1 receptor which holds α1 isoforms which elucidates why anterograde amnesia is such a 
common side effect of benzodiazepines (Mattila-Evenden et al., 2001). In addition, glutamate 
is one of the major neurotransmitters involved in memory formation and consolidation. When 
GABAA is over activated in cases of benzodiazepine use, the ability for glutamate to carry 
out its function is drastically hindered. 
 
BZ2 receptors hold the α2 isoform which bring about the effects to reduce anxiety and 
increase muscle relaxation (Sieghart, 1992) (Kaufmann et al., 2003). The variation of clinical 
effects brought about by different benzodiazepines are due to the drugs binding to BZ 
receptors with varying degrees of affinity as well as discrepancies in α subunit isoform 
amounts in different GABAA receptors as well as the binding site locality within the central 























Figure 4.  An illustration of the parts of the brain and limbic system affected by drugs of 
abuse. The limbic dopamine system is located in the ventral tegmental area (VTA) of the 
midbrain. This projects onto the nucleus accumbens (NA). The amygdala (A), prefrontal 
cortex (PFC) and hippocampus (HC) send excitary neurons to the nucleus accmbens. 
(Robbins and Everitt, 1999) 
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All of the drugs housed under the benzodiazepine class of drugs have similar effects on the 
user causing impaired judgment, loss of motor control, lack of coordination, decreased 
reaction time, dizziness, loss of memory while under the influence, confusion, drowsiness, 
respiratory depression with higher doses, slurred speech. 
 
All of the aforementioned reactions can last anywhere from 4-12 hours or more and because 
of these adverse effects, driving under the influence of benzodiazepines is dangerous and 
becoming an increasingly bigger problem (Barker et al., 2004). These drugs inhibit 
psychomotor and cognitive function which in turn affects reaction time and driving skills 
significantly (Linnoila et al., 1990, Stone et al., 2015). Meta-analysis research studies suggest 
road traffic collisions are 60-80% more likely with benzodiazepine use (Dassanayake et al., 
2011). When used alongside alcohol the danger is even more prevalent as both drugs are 
central nervous system depressants which have a synergetic effect on GABA receptors and 
increase toxicity of each other when taken together. 
 
1.3 Epidemiological Prevalence of Benzodiazepines 
 
Research and surveys indicate that benzodiazepines are one of the most commonly 
prescribed drugs in the world, with approximately 16 million prescriptions in 2015 (HSCIC, 
2016). An estimated 500,000 to 1 million of prescribed patients are thought to be 
dependent on benzodiazepines (Ashton, 2004). The use of prescription medicine in general, 
has steadily increased in the last decades as a result of, but not entirely, the changing age 
demographics; with an increasing number of the population now considered elderly. Also, 
the use of anxiolytic and hypnotic drugs may have always been excessive and inappropriate, 
based on dependence and habituation (Lader, 1991). However, the prevalence of abuse is of 
increasing concern. In the UK, participants of surveys who said they had driven under the 
influence of drugs at least once or twice in the last 12 months; 31 percent admitted to being 
under the influence of sedative drugs in that period (Daamen et al., 2012). In a separate 
study by Oliver et al. 2006, biological samples were tested for 3,616 people who had been 
pre-screened for drug driving. Of these 75 percent were found to have drugs in their system 
with the most common drug found to be benzodiazepines.  
 
A study carried out by Simon et al. (1996), found that 3 factors determine length of use and 
consequently likelihood of addiction. The patient’s age, the use of high potency drugs (such 
as clonazepam) and dosage of drugs in the initial prescription (Simon et al., 1996). This is 
further verified by another study in the United States in 1997 which found that age, 
frequent or daily use as well as prescriptions provided by other than a general practitioner 
were all associated with long term use; an average of 13 years (Isacson, 1997). Research 
suggests that young adults involved in frequent non-medical use are more likely to be 
addicted. A study of 356 participants aged 18-28, who had used benzodiazepines at least 
once in the last 90 days, elucidated that 12.6% met the dependence criteria (Kurtz, Buttram 
and Surratt, 2016). In contrast, medical use, especially long term, is most prevalent among 
females over the age of 50 (Dupont, 1988). Benzodiazepines with stronger hypnotic 
properties are considered of higher risk due to likelihood of increased dependency from 
continuous use. Moreover, those on higher dosages are more prone to dependence. This is 
evident from the fact when withdrawing primary care studies suggest gradual dose 
reduction over at least a period of 10 weeks to effectively obtain long term abstinence 
(Denis et al., 2013). 
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Recreational benzodiazepine use is becoming more and more widespread and although the 
size of the population is not definitive, estimates suggest that 200,000 people use 
benzodiazepines illicitly in the UK. At least half of amphetamine, cocaine and opiate users as 
well as alcoholics take benzodiazepines concurrently with their drug of choice. (Ashton, 
2002; Ashton 2004). Reasons for this are to bring users down from stimulant drugs such as 
cocaine or to reduce the withdrawal effects of other drugs. Some users say illicit drug 
effects are augmented when taken with benzodiazepines (Ashton, 2005), such as in the case 
of opiates where both are CNS depressants resulting in a synergetic potentiating effect. 
Some users will take benzodiazepines as the primary recreational drug, usually on high 
doses and short acting time via means of intravenous injection (Ashton, 2002).  
 
In the United States in 2008 there were more than 270,000 visits to the emergency 
department from illicit benzodiazepine use, of which 40% involved alcohol (Substance 
Abuse and Mental Health Services Administration (SAMHSA), 2011). This number further 
increased to 426,000 people in 2011, of which 24.2% involved alcohol (Marmorstein, 2011). 
In addition to the aforementioned figures, there are an estimated 85 million people who are 
legally prescribed benzodiazepines for outpatients with anxiety and mood disorders only. It 
is evident the prevalence of benzodiazepine use in the United States is rife (Moloney, 
Konrad and Zimmer, 2011). In a Canadian study, approximately 8.4% of the total population 
used at least one benzodiazepine in 2006 with 3.5% of the prescriptions exceeding 100 days 
use (Cunningham, Hanley and Morgan, 2010). 
 
The availability of these drugs are common place and sources of illicit benzodiazepines 
predominantly come from general practitioner prescriptions or thefts from chemists and 
pharmaceutical warehouses as well on the internet through black market websites (Ashton, 
2004; Grzybowski, 2004). 
 
Although benzodiazepines are considered to have a high LD50 when compared to other CNS 
depressants such as barbituates, tolerance grows exponentially in regard to their sedative 
activity. Although some patients suffering from insomnia report continual hypnotic efficacy 
of the drug, this may be due to the prevention of rebound insomnia; a withdrawal effect of 
benzodiazepines. The majority of hypnotic benzodiazepine users will gradually increase their 
dosage, at times to over the recommended daily prescribed limit, due to increased tolerance 
where a higher dose is required for the same effect provided by the initial prescription. 
Increased tolerance is also evident as it is commonplace for individuals suffering from 
sleeping disorders to take two or more benzodiazepines daily and concomitantly (Morin, 
Bélanger, Bastien and Vallières, 2005; Poyares, Guilleminault, Ohayon and Tufik, 2004). For 
their anticonvulsant and muscle relaxant effects, the potency of benzodiazepines are 
significantly reduced after two months of constant use (Gerecke, 1983), suggesting that for 
long term treatment of muscle spasticity and seizures, benzodiazepines are not appropriate. 
Although slower than sedative tolerance builds up, which takes a matter of days or weeks of 
continual use (Ashton, 2005). Research has shown that cognitive impairment is likely and 
long-term users of benzodiazepines suffer from shortfalls in all 12 of the cognitive domains 
which include attention, memory, learning and visuo-spatial capability to name a few 
(Barker, 2004). In terms of anxiolytic effects, tolerance build up is slow and can take a few 
months. Even so, research shows dosage escalation is common, where multiple 
benzodiazepines are taken following the first losing efficacy. A previous study indicated over 
a quarter of participants were taking two anxiolytic benzodiazepines (Ashton, 1987). 
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Furthermore, clinical observation indicates chronic benzodiazepine use to have no effect in 
controlling anxiety disorders, but in some cases amplifying it (Ashton, 2005). 
Public Health England found that between 2017 and 2018, 1.4million adults (3% of the adult 
population) had received and dispensed one or more prescriptions for benzodiazepines. This 
is not inclusive of illicit use. In the UK alone, an estimated 500,000 to a million patients who 
are prescribed benzodiazepines are dependent on them (Ashton, 2004). A large population of 
the number are elderly and female who regularly take hypnotic benzodiazepines and their 
usage continues to grow (Curran et al., 2003). 
 
Studies show the likelihood of dependence increases with long term use of benzodiazepines, 
higher dosage usage and usage of short acting benzodiazepines. Key indicators of 
dependence become evident during dosage reduction or complete cessation of use.  Another 
means of inferring dependence is through benzodiazepine users other drug habits. People 
with drug and alcohol dependence are more likely to develop addiction to benzodiazepines 
(Johansson, 2003). 
 
Withdrawal symptoms of benzodiazepine use includes but are not limited to palpitations, 
perceptual distortions, panic attacks, anxiety, agitation, muscular pain, weight loss, 
restlessness, sweating, sensory hypersensitivity, cognitive decline and severe sleep 
disturbance. Those on a higher dosage are more likely to experience more severe and 
sometimes life threating withdrawal symptoms such as seizures and psychotic reactions 
(Petursson, 1994). Specific studies show that all subjects suffer from some of the 
constellation of withdrawal symptoms mentioned above; namely anxiety, restlessness, 
agitation and sleep disturbance (Petursson and Lader, 1981). 
 
Research shows that withdrawal is often protracted with numerous cases indicating that 
patients can take up to 3-4 years to fully recover and are often left with underlying symptoms 
directly attributed to benzodiazepine use; such as tinnitus (Ashton, 2002). In the UK alone it 
is estimated that over a 100,000 people would be willing to engage in services to help 




















Figure 5. Demonstrates the proportion of adults in England receiving a prescription between 








Diazepam, the second benzodiazepine approved for human usage (Baselt, 2020) is one of the 
most widely prescribed benzodiazepines (Griffin et al., 2013). The structural makeup 
accounts for its long acting, medium potency.  At position 1 an alky group is present and the 
specific structure and size allowing for maximal agonist activation. The essential carbonyl 
group required for pharmacological activity via receptor binding is present at position 2. At 
position 3 a small hydrogen substituent is present to allow for maximum efficacy. Position 4 
to 5 has the unsaturated double bond to also allow for maximum effectiveness. Position 5 has 
the phenyl ring for peak action. At position 7 a highly electronegative chloride atom is 
present giving its strong sedative properties. 
 
Dosages vary and are dependent on patient to patient health conditions, but typical daily 
intake is between 2 and 40mg (Baselt, 2020). Diazepam absorbs relatively quickly and peak 
plasma concentrations are seen anywhere between 15 and 90 minutes following 
administration, however this can be slowed via the intake of fatty meals. Diazepam has an 
average distribution volume of 0.7-2.6L/Kg (Baselt, 2020). It metabolises in the liver to N-
desmethyldiazepam, also known as nordiazepam, as well as the metabolites oxazepam and 
temazepam (Wolff et al., 2003). The primary metabolites are pharmacologically active and 
has a lengthy elimination half-life which may contribute to prolongation of clinical efficacy 
(Nilsson, 1991). In young adults the elimination phase occurs at a rate of 20-30mL/min, 
however this can be extended by multiple dosing (Griffin et al., 2013). Toxic effects of this 
drug and its metabolites can be seen when concentrations exceed 1500 μg/L (Moffat, 
Osselton, Widdop and Watts, 2011). As mentioned prior, anxiolytics tend to have a longer 
tolerance build-up of approximately a few months. 
 
Diazepam has strong sedative properties and can cause anterograde memory deficits, 
severe drowsiness (Jongen, Vuurman, Ramaekers and Vermeeren, 2018) as well as 
impairment in perceptual speed resulting in driving too fast, coordination skills resulting in 
failure of lane observance (Dubois, Bédard and Weaver, 2008) and reaction time. In 
addition, flicker fusion discrimination and visual parameters are affected (Seppala et al, 

























































Figure 7. Mean blood concentration of diazepam as a function of the dosage (0.1 vs. 0.3 
mg/kg) and time at which blood samples were collected: before intake of the drug (0) and at 
20, 30, 40, 50, 60, 75, 90, 120, 180, and 240 min after intake of the drug. Vertical bars 







Oxazepam is a benzodiazepine derivative that has been used clinically as an antianxiety agent 
since 1965 (Baselt, 2020). At position 1 of the oxazepam structure a hydrogen is attached to 
the nitrogen which allows for good biological activity when consumed and may be suitable 
for people who do not require a drug as strong as the likes of diazepam. At position 2, the 
essential carbonyl group required for pharmacological activity is present.  At position 3 a 
polar hydroxyl group being present allows the drug to provide therapeutic aid when a short 
acting dug is required and can be excreted quickly. Being highly polar the drug is excreted 
without phase 1 metabolism. Position 4 to 5 retains its unsaturated double bond in order to 
not lose its activity. At position 7, an electronegative chloro group covalently bonded is 
present which gives the compound its characteristic sedative properties. 
 
Although a prescribed benzodiazepine in its own respect, it is a metabolite of various other 
benzodiazepines including but not limited to diazepam and temazepam. It is itself 
metabolised into glucuronide conjugates. Usually, prescribed as an anxiolytic, its effect on 
GABAA receptors also produces a hypnotic effect (Greenblatt, 2012). Typical doses vary 
significantly, but maximum daily doses are limited to 30mg (Baselt, 2020). Due to its short 
acting period once daily anxiolytic treatment is not viable and dosages must be sub-divided 
and given 3-4 times a day for anxiolytic effects to be therapeutically effective (Greenblatt, 
Shader, Divoll and Harmatz, 1981., Baselt, 2020).  Peak absorption time is approximately 2-4 
hours, and onset of effects at 3 hours. Distribution volume ranges from 0.7 to 1.6L/Kg 
(Baselt, 2020). it is noteworthy to mention, renal disease will increase the volume of 
distribution and extend half-life. Oxazepam is rapidly conjugated with glucuronic acid and 
excreted in the urine. Oxazepam glucuronide, an inactive metabolite, is found to a limited 
trace amount in serum and accounts for 61% of an oral dose in the 48 hour urine (Baselt, 
2020). Following detailed meta-analysis of 26 studies on plasma-concentrations, the DRUID 
project interpreted that 330µg/L of oxazepam was the corresponding level of impairment 
caused by 50mg of alcohol per 100ml of blood. 
 
Diazepam is extensively metabolised via oxidative pathways into nordiazepam and 
temazepam which are then both metabolised into oxazepam. As a result, compliance 
monitoring is a cause for concern. Patients who are prescribed diazepam often will not test 
positive for the pro-drug but rather one or multiple of the pharmacologically active 
metabolised agents. Patterns emerge when patients take diazepam frequently as opposed to a 
prescribed as needed basis. Those taking diazepam regularly and over the long term 
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commonly test for all three metabolites (see Figure 8). It is often the case that high levels of 
the metabolites are detected. Infrequent diazepam users generally show oxazepam as the only 
active metabolite and it is not uncommon to find trace levels of oxazepam (<300ng/mL) even 















































Figure 9.  tabulates a toxicology report for all three active matabolites 
present in the body from a frequent diazepam user (Gunn,2015). 
Figure 10. tabulates a toxicology report for a semi-recent diazepam 






Temazepam has been used clinically as a hypnotic drug since 1979 (Baselt, 2020). At 
position 1 of the temazepam moiety an alky group is present allowing for maximal activity. 
The keto group as present in the majority of benzodiazepines can also be found in the 
temazepam structure giving it its characteristic properties. At position 3 a polar hydroxyl 
group being present allows for short action of the drug and can be excreted quickly via urine. 
Temazepam shows a short phase 1 reaction via a demethylation reaction forming oxazepam 
before being excreted. Position 4 to 5 has the unsaturated double bond to also allow for 
maximum effectiveness. At position 7, a chloride group is present allowing for good potency, 
however, not as potent as clonazepam and flunitrazepam which have the nitro groups in the 
same position.  
 
As a hypnotic drug, temazepam is prescribed to aid sleep disorders as well as those suffering 
withdrawal from Class A drugs. Typical daily doses are 10-20mg with a peak absorption rate 
of 2-3 hours and a half-life of 8-13 hours. Peak plasma concentrations in the elderly given a 
10mg dose averaged at 305µg/L, while in young healthy men averaged at 668µg/L with a 
20mg dose (Baselt, 2020). Although a medium acting benzodiazepine, a common residual 
side effect can leave minor sedation up to 24 hours after consumption but does not 
significantly impair driving ability (Verster et al., 2004). Overdose may produce loss of 
consciousness and mild to moderate respiratory depression (Baselt, 2020). Fatal cases of 
temazepam, solely due to this drug, have been recorded in femoral blood concentrations at 
10,000µg/L Akin to oxazepam, temazepam is a metabolite of other benzodiazepines such as 
diazepam and is itself demethylated to oxazepam and then further into glucuronide 
conjugates. The major metabolite of temazepam is the O-conjugate of temazepam (90%) and 
the minor being O-conjugate of N- desmethyl temazepam (7%). Excretion of temazepam was 






















Clonazepam is a benzodiazepine derivate that was approved for use as an anticonvulsant in 
the US in 1975 Baselt, 2020). At position 1 a hydrogen atom is present attached to the 
nitrogen atom. At position 2, the essential carbonyl group required for pharmacological 
activity is present. There is no hydroxyl group present at position 3 that can be seen in 
oxazepam, temazepam and lorazepeam. As a result clonazepam is a long action duration 
drug. Position 4 to 5 has the unsaturated double bond to also allow for maximum 
effectiveness. Position 5 has the phenyl ring for peak action. In addition to this the aromatic 
ring has a electron withdrawing chloride group substituted at the ortho position to further 
increase its potency.  Position 7 has an NO2 group with electron withdrawing effects stronger 
than that of the halogens. As a result, the potency of the drug is even further increased. Out of 
the drugs in question clonazepam has the highest potency and is the longest acting in the 
body, without any active metabolites, with a half-life of up to 40 hours. 
 
Daily dosage ranges from 0.5-2mg up to 4 times a day (Baselt, 2020). Entirely absorbed after 
oral administration this benzodiazepine sees greatest plasma concentration between 1 and 4 
hours, with an onset of action in less than 1 hour. Distribution volume is typically 1.5-
4.4L/Kg (Baselt, 2020). It is completely eliminated from the body at a typical range of 30 and 
40 hours. Peak blood concentrations of clonazepam range from 6.5–13.5µg/L and were 
reached within 1–2 hours following a single 2 mg oral dose of clonazepam in healthy adults. 
(Riss, Cloyd, Gates and Collins, 2008). An acute clonazepam dose of 14 to 32 mg taken orally 
produced a plasma concentration of 69 µg/L which eludes toxicity symptoms such as antaxia 
(Welch et al., 1977). Plasma level of more than 80µg/L is considered to be toxic while the 
therapeutic level ranging between 10 µg/L and 50µg/L. Coma-tose lethal doses were found to 
occur at 1000µg/L (Regenthal et al., 1999) 
 
With regard to driving, Clonazepam affects psychomotor performance by impairing flicker 
fusion, reaction times and memory (van der Meyden, 1989) and therefore, being in charge of 











A 3- hydroxy benzodiazepine, structurally related to oxazepam and temazepam has been used 
clinically as a anti-anxiety agent since 1971 (Baselt, 2020). At position 1 of the lorazepam 
structure a hydrogen atom is present attached to the nitrogen atom. At position 2, the essential 
carbonyl group required for pharmacological activity is present. At position 3 the hydroxyl 
group providing high polarity, similarly to oxazepam and temaepam, allows for short action 
of the drug and can be excreted quickly. Being highly polar the drug is excreted without 
phase 1 metabolism. Lorazepam is one of the strongest and most potent drugs on the market 
with a maximum half-life of up to 24 hours. 
 
Pure lorazepam is a white powder that is almost completely insoluble in water and oil. For 
medical use lorazepam is prescribed mainly as tablets or a solution to inject via deep 
intramuscular injection or intravenous injection where absorption is rapid and complete. In 
some medical settings the drug can also be prescribed as a sublingual tablet which can reach 
peak drug concentration in 60 minutes (Fox et al., 2011), or an oral solution or a skin patch. 
Dosage varies from patient to patient, however a maximum daily dose of 4mg is given with 
onset starting within 30 minutes. Peak absorption takes 2 hours (Greenblatt, 2012) with a 
distribution volume of 0.9-1.3L/Kg (Baselt, 2020) 
Plasma concentrations for this benzodiazepine are typically measured between 300-600µg/L 
and toxic effects are seen at concentrations above 1500µg/L (similar to that of Diazepam). 
This correlates to an approximate administration of a 100-200mg dose. Lorazepam 
metabolises to the inactive glucuronide and 50% is excreted within 24 hours.  
 
Common side effects of lorazepam are weakness and disorientation. Psychomotor skills are 
significantly impaired due to slowed reaction time and impaired flicker fusion and the 






























































Figure 14. Comparison of blood concentration following intramuscular, intravenous 
and oral administration of 5mg single dose of Lorazepam. Note: ng/ml= µg/L  (Elliot, 
1976). 
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Chemical structure of Flunitrazepam- At position 1 a hydrogen atom is present attached to the 
nitrogen atom. At position 2, the essential carbonyl group required for pharmacological 
activity is present. Position 4 to 5 has the unsaturated double bond to also allow for maximum 
effectiveness. Position 5 has the phenyl ring for peak action. In addition to this the aromatic 
ring has a fluoro group substituted at the ortho position to further increase its potency. In 
position 7, the NO2 group is highly electronegative and in dire need of electrons giving it 
strong electron withdrawing properties, thereby increasing its efficacy, giving the compound 
its strong characteristic sedative properties.    
 
Flunitrazepam is used primarily to aid severe insomnia, as a pre medication for surgical 
procedures and/or for inducing anaesthesia. In addition to this, since the early 1990’s it has 
also been used to reduce the depression that drugs such as methamphetamines and cocaine 
cause because of the muscle relaxation and anxiety reduction effects (Gambi et al., 1999). 
Dosages are typically in the range of 0.5-2mg due to its highly potent nature. 
Flunitrazepam is considered a medium acting benzodiazepine, however some studies may 
suggest it long acting due to its upper limit of half-life being 35 hours. Pharmacokinetic 
characteristics allow the drug to be rapidly metabolised to desmethyl flunitrazepam and 7-
aminoflunitrazepam which are active and inactive respectively (Moffat, Osselton, Widdop 
and Watts, 2011). Peak plasma concentrations occur an hour after oral administration of a 
single dose while patients who administer the drug daily for a month or more, of continuous 
use can expect to see peak concentrations after 3 hours (Moffat, Osselton, Widdop and 
Clarke, 2004). The common concentration range for someone using this drug therapeutically 
at night is between 5 and 20μg/L and between 10 and 50μg/L for those who are arrested for 
DUI (Jones, Holmgren and Kugelberg, 2007; Robertson and Drummer, 1998; Baselt, 2008). 
Furthermore, some studies propose that high doses of flunitrazepam causes aggression in 
some indivduals (Bramness et al., 2006). This fact alone indicates the dangers of driving 
under the influence of flunitrazepam given its powerful hypnotic properties and being 
prescribed to use at night before sleep. 
 
All of the above drugs used in conjunction with alcohol can increase the intoxication of 
alcohol. Not used as commonly in the UK compared to other European countries, between 
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the years 2001 and 2003, Norway was suffering a flunitrazepam epidemic. The number of 
suspected drug drivers under the influence of said drug increased three fold and number of 
cases peaked at approximately 2100 cases (Bramness, Skurtveit and Mørland, 2006).  
 
 
1.11 DRUID report  
 
The Driving under the influence of drugs, alcohol and medicines (DRUID) report is a 
research project undertaken in Europe and is a compilation of work which comprises of 
detailed information on research projects undertaken, epidemiological research, policing, 
classification of drugs and medicine, rehabilitation following conviction and the withdrawal 
of driving licences. In addition, information is present on dissemination and guidelines. 
(Schulze, 2013). The DRUID report findings suggest that the most frequently found 
substances that cause serious injury, following alcohol and THC, are benzodiazepines 
(alcohol serious injury range:14.1-30.2%, THC serious injury range: 0.5-2.3%, 
Benzodiazepines serious injury range: 0.0-2.3%) (Schulze, 2013). In addition to this, the 
study also found that accidents causing death was second highest for benzodiazepines, 
following alcohol (alcohol causing death range: 15.6-38.9%, benzodiazepines causing death 
range: 0.0-5.2%) (Schulze, 2013).  
 
Based on roadside tests and experimental studies, it was found that both benzodiazepines and 
medicinal opioids were most prevalent in middle aged and older female drivers (generally > 
35) (Olfson, King and Schoenbaum, 2015, Gerlach, Wiechers and Maust, 2018) . However, it 
is note-worthy to mention that the studies in the report which suggest serious injury or death 
by use of benzodiazepines is most prevalently found in male drivers aged >35 and most were 
detected with benzodiazepines in conjunction with other psychoactive substances such as 





















1.12 Meta-analysis of road traffic toxicology study: Benzodiazepines  
 
Figure 16. Graph exemplifying the percentage of the population who use benzodiapeines by sex and age. 




Meta-Analysis is the examination of data from numerous different independent studies on the 
same subject which are collated and analysed to determine overall trend. In the DRUID 
project, 605 different publications were taken into account for medicines and illicit drugs and 
the results suggest that with increasing dosages, certain drugs (especially anxiolytics, 
antidepressants and sedatives) caused a high degree of impairment and negatively impacted 
motor skills (Schulze et al., 2012). In the study, degree of impairment was given a whole 
number integer with 0 being no impairment and going all the way up to 571 for the 
benzodiazepine lorazepam. All other drugs fell in between this range. The greatest 
impairment of a substance is a crucial factor when estimating the danger associated with use 
of that substance; however, consideration must be made to maximum impairment being of 
short or long duration. As a result, for each substance that had been the subject of sufficient 
experimental studies, the project used the impairment function to construct an impairment 
curve, showing the degree of impairment over time. Once the curve was constructed, the 
‘area under the curve’ was calculated to capture both the level of impairment and the 
duration. To exclude minor effects, a line was drawn to represent impairment equivalent to 
0.3 g/l BAC. The final measure of the danger of a substance, the ‘degree of impairment’, 
indicates the area between the approximation curve and the minor impairment line, thus 
capturing in a single parameter both the intensity (magnitude of impaired effects) and 
duration of impairment (DRUID, 2013). 
In the case of diazepam, the most commonly prescribed benzodiazepine, a dosage of 5mg 
predicted a degree of impairment of 17. If this dosage is doubled to 10mg the predicted 
degree of impairment increases exponentially to 57, also the case at 20mg where degree of 
impairment increases to 171 signifying the rapid loss of driving skills with increases in 
dosage. Interestingly, however, the benzodiazepine temazepam which comes under the class 
of drug hypnotic and sedative causes 0 impairment from a 10mg dose. This increases to 40 
when dosage is doubled to 20mg. The study suggests that lorazepam and flunitrazepam cause 
the most concern when looking at medicinal drugs as a 2mg dose of lorazepam causes a 
degree of impairment of 418 which dramatically increases to 571 (the highest number in the 
listing) when dosage is increased by a fractional 0.5mg. For a 2mg dosage of flunitrazepam, it 
is even higher with a degree of impairment of 461 in comparison to 418 for the same dosage 
of lorazepam (Schulze et al., 2012). 
 
The DRUID project also evaluated roadside screening devices to determine if enforcement 
officials can confidently use these systems to screen motorists for drug use and subsequently 
convict drug-drivers. All devices screened oral fluid as it provides the most accurate 
information on recent drug use in both practical and analytical terms (Schulze, 2013). In 
addition to this, clinical signs indicating drug use such as uncoordinated movement and 
bloodshot eyes were appraised to see if these indicators are an effective means of pre-
screening suspected drivers. This was done due to the time and monetary cost of doing 
roadside oral tests. In addition to this, in the UK roadside screenings for benzodiazepines are 
not carried out as oral fluid cannot confirm that the individual is impaired from driving at that 
moment in time, only a blood sample can confirm this (Drummer, 2009). The evaluation 
focused on aspects relating to the above-mentioned points in addition to hygiene aspects as 
well as an officer’s view of ease of use of the device. Of 13 devices used the results showed 
that 8 of them were cost beneficial. 
 
 
The approach the board took was setting a specific limit for each of the drugs based on 
potency and its overall effect on driving skills at different concentrations. As a result, any 
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driver found guilty of exceeding said limit could be prosecuted without the prerequisite that 
he/she was impaired from being in charge of a motor vehicle. However, due to certain 
medicinal drugs, primarily benzodiazepines, being prescribed so widely for both short- and 
long-term use (at least a million people prescribed in 2005) (Ashton, 2005); considerations 
had to be made. The board coordinating the Wolff report evaluated epidemiological and 
experimental research studies, in relation to blood drug concentrations and driving behaviour. 
Considerations were made taking into account practical and ethical implications. In contrast 
to this, the board had not only the prescribed patients to consider, when setting limits, but 
also the illicit use of benzodiazepines. According to the ‘World Drug Report’ of 2011, 
benzodiazepine seizures had increased by more than 50 percent in 2011 alone; implying these 
drugs are being sold outside the channels of health authorities and through illicit means often 
in the form of illegal online pharmacies (Wolff et al., 2013). In turn, making as close to true 
estimations on the extent of illicit benzodiazepine use is problematic. 
 
Findings from the vast drug drive research compiled in the Wolff report found that those 
using benzodiazepines posed a 62% increase in risk of road traffic accidents compared to 
those who do not take benzodiazepines. Reviews suggest this value can increase to 290% 
(Engeland, Skurtveit, & Morland, 2007) In addition to this, findings also suggest that long 
acting benzodiazepines will further increase the risk of road traffic accidents in comparison to 
their short acting counter parts highlighting an increased need and awareness for those 
driving following benzodiazepine ingestion (Barbone et al, 1998). One study carried out by 
Orriols (2009) which evaluated 3 French national databases over a 3-year period (2005-2008) 
comprising of 72,000 drivers found that those with prescriptions for 3 or more 
benzodiazepines posed a higher risk of accident as well as those taking anxiolytic 
benzodiazepines over hypnotics. Those taking anxiolytics were more at risk of causing road 
traffic accidents regardless of half-life (Dassanayake et al, 2011). Another study by Thomas 
(1998) had findings highlighting that those aged 65 or over would be an increased hazard to 
the road when taking longer acting benzodiazepines and consuming them in larger amounts. 
The National institute of Forensic Toxicology analyses 818 Danish drivers who were 
suspected of driving under the influence of drugs or alcohol and found that benzodiazepines 
were detected in impaired drivers at supra therapeutic concentrations in blood as opposed to 
levels that would be seen under normal prescribed levels.  
 
After evaluating all of the data and research the panel for the Wolff report recommended 
threshold limits for those benzodiazepines which posed a greater risk of road traffic 
accidents, especially when taken above therapeutic guidelines. The threshold recommended 
for diazepam was 550µg/L, clonazepam 50µg/L, lorazepam 100µg/L, flunitrazepam 
300µg/L. Special consideration was taken when setting limits for oxazepam (300µg/L) and 
temazepam (1000µg/L) based on the understanding that these drugs are common metabolites 












1.13Fixed driving limits England and Wales 
 
 The Wolff report provides detailed information on driving under the influence of an array of 
drugs and is supported by the department of transport. The panel in charge of assembling 
data, results and findings brought together expert advice on the matter. Prior to 2020, 
impairment had to be proven via means of a Field Impairment Test (FIT) test. This method 
was deemed unsuitable as certain tasks during the test were too difficult and could result in a 
conviction even if those suspected were not drug impaired. Blood concentration analysis has 
been proposed as a more effective method (O’Keefe, 2013) due to allowing broader spectrum 
testing and better correlation in blood and pharmacological effect over other analysis of urine 
or saliva samples (Langel et al., 2014). Time delay, storage conditions and degradation are 
also important factors to consider. Due to the need of a professionally trained medic to 
withdraw a sample of blood, there is often a time delay between a drugged driver being 
stopped, assessed, arrested, taken back to the station and then a sample of blood taken. This is 
likely to have an effect on blood concentration levels as the benzodiazepines metabolised; 
with emphasis on the shorter acting drugs. Furthermore, a study by (Melo, Bastos and 
Teixeira, 2012) found that freezer conditions allowed stability of concentration for 6 months. 
However, at positive temperatures such as fridge or room temperature, significant 
degradation took place. Analyte degradation before analysis if often a result of chemical or 
physical decomposition due to drug instability. An example of this is diazepam is prone to 
hydrolyisis while flunitrazepam is associated with substantial degradation in a biological 
sample within a day when exposed to sunlight (Benhamou-Batut, 1994). Thus, incorrect 
storage conditions will significantly impact final blood concentration levels calculated. As a 




1.14 Section 5A of Road Traffic Act 
 
The effects of benzodiazepines on driving have been recorded extensively, demonstrating that 
they contribute to an increased risk of road traffic collisions and research supports this view 
(Dassanayake et al., 2011). Section 5A came into force on 2nd March 2015 and has specified 
new concentration limits for controlled drugs, when driving. The drugs are broadly 
categorised into two groups; medicinal drugs and drugs of abuse. The medicinal drugs have 
been given a relatively high limit utilising a risk threshold methodology in order to not 
dissuade patients from using prescribed medication. For the drugs of abuse a zero-tolerance 
approach has been utilised which only take into account levels for accidental exposure 
(Rooney et al., 2016). Rooney et al (2016) found that the majority of drivers caught under the 
influence of drugs had concentrations of benzodiazepines under the threshold stipulated in 
Section 5A. Of 545 samples, those found driving under the influence of diazepam (limit: 
550µg/L) 38.2% of those were found to be over the limit with a mean concentration of 
619µg/L. In relation to oxazepam (limit: 300µg/L) 14.7% of samples were found to be over 
the limit with a mean concentration of 173µg/L. With regard to temazepam (limit: 1000µg/L) 
only 5.8% of samples were found to be over the limit with a mean of 280µg/L. In terms of 
lorazepam, this was found in less than 10 cases and did not warrant inclusion in this study. 
Irrespective of this, under the new legislation an automatic defence is included for motorists 





Table 2: List of drugs stipulated in Section 5a of the Road Traffic Act and their respective 
limits in blood. (Forensic Science Regulator FSR-C-133. 2016) 










Amphetamine 250 20 314 
Benzoylecgonine  50 20 64 
Clonazepam 50 20 64 
Cocaine 10 35 17 
Delta-9-Tetrahydrocannabinol 2 30 3 
Diazepam 550 20 689 
Flunitrazepam  300 25 402 
Ketamine 20 20 27 
Lorazepam  100 25 135 
Lysergic Acid Diethylamide 1 45 2 
Methadone 500 25 668 
Methylamphetamine  10 40 1 
Methylenedioxymethamphetamine 10 25 15 
6-Monoacetylmorphine 5 35 8 
Morphine 80 25 108 
Oxazepam 300 20 377 
Temazepam 1000 20 1257 
 
 
There are approximately 20 million prescriptions issued every year for the drugs covered in 
the offences under Section 5a; as surveyed by the department of transport. A 2016 study 
collected blood samples from drivers during 2010-2012 and found that benzodiazepines are 
the second most common drug in driving under the influence of drugs cases in the United 
Kingdom (Rooney et al., 2016). Due to the public health risk associated with these drugs, it is 
imperative to have strict guidelines on prescribed use and zero tolerance for recreational use. 
To further support the need for such an approach, a study suggests Drug recognition experts 
(DRE) observations are least likely (after alcohol) to spot CNS depressant use (41%) (Talpins 
and Hayes, 2004). It is noteworthy to mention, DRE do not operate in the UK, however, they 
use a similar Field Impairment Test (FIT) which both include the modified romberg balance, 
the walk and turn, the one leg stand, and the finger to nose test. Anyone arrested for these 
offences can offer a medical defence stipulating the drug was lawfully prescribed, supplied or 
purchased over the counter for medical purposes and was taken in accordance with advice 










1.15 Chromatographic Analytical Techniques 
 
The combination of chromatographic analytical techniques has been intensively researched 
and sought after for decades due to its accurate, sensitive and highly specific nature. Due to 
certain limitations and irreconcilability issues regarding the existing mass spectrometer ion 
sources of the era and the need for a continuous liquid stream; progress in the field was very 
limited. Nonetheless, research continued, and methods were built but the unreliability and 
temperamental nature of these first-generation methods meant uptake in clinical settings were 
minimal. This changed in the 1980’s when analytical chemist John Fenn heavily contributed 
to and developed the electrospray ion source (Fenn et al., 1989).  By the 1990’s, reliability 
and performance drastically improved as well as the price of the technology resulting in a 
huge number of laboratories, albeit mainly biochemistry centres, taking on this new 
technology. Although its primary major use was previously in the field of biochemical 
genetics and analysis of neonatal blood (Rashed et al., 1997), Liquid Chromatography- Mass 
Spectrometry (LC-MS) has become a standard in many fields owing to its ability to analyse a 
broad range of biological molecules over its previously developed counterpart; GC-MS. In 
addition to this, the steady increase in requiring LC separations in laboratories has also 
contributed to its success as LC-MS is more specific and can handle complex matrices better 
than LC alone (Ho et al. 2003). Added to this, one study found that although GC-MS has 
been the gold standard for drug analysis for a long time, LC-MS provides specific advantages 
such as ease and speed of sample extraction as well as shorter run times (Perez et al., 2016). 
Research suggests that studies where it is possible to use GC–MS with cold EI improves all 
the central performance aspects of GC–MS. This includes improving sample identification 
via the provision of enhanced molecular ions combined with improved mass spectral isomer 
and structural information (Kachhawaha et al., 2017). 
 
 
1.16 High Performance-Liquid Chromatography 
 
Chromatography has many forms and is an indispensable separation technique for the 
analysis of one or more components from a mixture that contains simple and/or complex 
molecules. It is a method based on the principle where molecules in a mixture are applied 
through the surface of a solid whereby the stationary phase separates from each other while 
moving with the aid of the mobile phase. Factors effecting the separation are the molecular 
characteristics such as adsorption, partition and affinity among their molecular weights 
(Goswami, 2015). 
 
A form of column chromatography which utilises high pressure to push a sample (the 
analyte) which is dissolved in a solvent (mobile phase) through a preconditioned column with 
a chromatographic packing material (stationary phase). HPLC separates the individual 
components of a sample on the basis of retention time. Retention time and elution time is 
dependent on the properties and nature of the analyte, mobile phase and stationary phase. 
When moving through the column, the analytes which have the strongest attraction for the 
stationary phase will elute slowest; thereby taking longer to pass through the column and 
resulting in a longer retention time. Conversely, those analytes with weakest interactions with 
the stationary phase will elute fastest with a shorter retention time. This process can be done 
via two methods. Gradient or isocratic elution. The latter ensures the makeup of the mobile 
phase remains constant for the whole process. However, the former changes the composition 
of the mobile phase, depending on user preference, allowing for dissociation from the 
stationary phase favouring analyte conditions (Olga and Karin 2017). 
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 1.17 Ionisation Sources of Mass Spectrometers 
 
Mass spectrometry relies on the principle of recognising an analyte molecule by charging it to 
an ionised state (either positive or negative ionisation mode) followed by analysis of the 
charged molecule. Many different mass spectrometer technologies exist which induce the 
ionisation of a parent molecule such as electron impact, chemical ionisation, fast atom 
bombardment, thermospray and electrospray (ESI) to name but a few (Keshishian et al., 
2007). The two most common are ESI and Atmospheric Chemical Ionisation (APCI). 
 The ESI technique is amongst the most popular of the ionisation techniques as it is 
appropriate for a wide range of drug types and can produce multiple high molecular liquid 
samples are pushed through a metal capillary while being sustained at a voltage of between 2 
and 5kV. The capillary tubing is positioned at an off-axis angle to the entrance of the mass 
spectrometer machinery in order to minimise contamination. The resulting formulation of 
highly charged droplets are then evaporated off via heat and dry nitrogen. Residual charged 
molecules then desorb from the sprayed droplets and are transferred through small apertures 
through the rest of the mass spectrometer which has a high vacuum (Kebarle, 2000). The use 
of ESI has specific advantages over other ion sources such as the limited fragmentation 
occurring due to only a small amount of energy required for the analyte. Therefore, we 
consider this method a ‘soft’ ionisation source. The primary advantage of this is further 
fragmentation can be made to occur if required by increasing voltage which works via 
increased collisions with nitrogen (Pitt, 2009). Furthermore, ESI is a process which is easy to 




1.18 Triple Quadrupole Mass Spectrometer 
 
Triple Quadrupole mass spectrometer consist of three separate segmentations, Q1, Q2 and 
Q3.  The first quadrupole, Q1, is an efficient mass filter which allow for specific m/z to pass 
through while diverting all others to waste. These m/z are the downstream products of the 
ionised parent molecule from the ES ion source. Specificity is high for the triple quad due to 
its utilisation of two mass filters consecutively where Q1 identifies and selects the parent ion. 
Q2 is known as the collision cell where ions from the former quad are selected and collided 
with a noble gas in order to produce fragment ions. The third quadrupole, Q3, selects the 
fragment m/z. In order for optimal efficiency the triple quad requires two parameters 
optimised for each of the target metabolites. Once parameters are established each metabolite 
is measured using a ‘selected reaction monitoring’ (SRM) scan event where the parent ion 
produces a specific fragment ion at that specific collision energy. When multiple metabolites 
are involved an MRM approach is used which also takes into account multiple product ions 
for one parent ion. The main advantages of MRM are high sensitivity, due to the two MS 
steps, as well good linear dynamic range; owing to the efficacy of the quadrupoles and ion 











1.19 Method Development 
 
Due to a high usage of benzodiazepines worldwide, there is a large body of research focused 
on the development of innovative, highly sensitive, and accurate methods to analyse this drug 
class and their inactive metabolites. The analysis of benzodiazepines in biological fluids is 
vital in clinical assays as well as in forensics and toxicological studies (Qriouet et al., 2019). 
Analytical method development and validation can significantly impact cost efficiency as 
well as the research time taken. It is an ongoing process that runs parallel to the research, by 
means of monitoring process efficiency so relevant adjustments can be made. The overall 
goal of method development is to ensure that the method goals are feasible before ultimately 
being subjected to a validation programme. During method validation ensuring parameters of 
the method are clearly defined and limitations and capabilities of the method are detailed. In 
the scope of this project, the office for Forensic Science Regulator have stipulated the 
requirements, common approach, analysis and reporting of the concentrations of certain 
drugs in relation to offences under Section 5A Road Traffic Act. This guidance comes in the 
form of a document titled ‘The analysis and reporting of Forensic Specimens In relation to 
S5A Road Traffic Act 1988 FSR-C-133 Draft (2016)’ to aid analysis of samples. The use of 
limits guidance is stipulated in the document ‘Section 5A Road Traffic Act 1988 Use of 
limits FSR-G-221 (2020)’, while the validation parameters and guidance can be found in 
‘Validation FSR-G-201 (2020)’. Laboratories undertaking analysis of blood samples must 
also comply with quality standards as follows: It shall be accredited to ISO 17025 [A]. The 
analysis of blood samples shall be specifically listed in the scope of accreditation. It shall 
comply with the codes of practice and conduct. The laboratory should comply with the 
guidance on forensic toxicology issued by the United Kingdom and Ireland association of 
Forensic Toxicologists. 
 
Method development involves numerous stages and can take a number of months before it is 
fully complete. The procedure typically includes sampling, sample preparation, analysis, 
calibration and data evaluation and reporting. This process of bioanalysis can take time due to 
the complex nature of matrices, such as blood and plasma, and require rigorous sample 
preparation prior to injection into an analytical instrument. Information about the sample’s 
chemical properties, reactivity, volatility, polarity and stability should all be investigated and 
compiled before carrying out field work. Once this is done a suitable sample preparation 
technique has to be devised which give the cleanest extractions with the highest efficiency. 
Alongside this, internal standards which can effectively compensate for matrix effects must 
be chosen in order to achieve accurate results. Analyte concentrations also need to be known 
to decide upper and lower limits of detection and quantification. 
 
Although a vast array of extraction techniques are well established in the process of method 
development and validation, such as Protein Precipitation (PPT), Solid phase microextraction 
(SPME), Stir bar sorptive extraction (SBSE), Microextraction by packed sorbent (MEPS), the 
most common extraction techniques are still Liquid- liquid extraction (LLE) and Solid phase 
extraction (SPE) due to their universal applicability in most areas of study. 
Solid phase extraction works through the mixing of the sample (in the liquid phase) and an 
adsorbent (in the stationary phase). The first step will require conditioning of the stationary 
phase column where the site of retention is wetted via means of an organic solvent. Following 
 31 
this, in order to improve extraction yield, washing is required whereby interferences that are 
weakly attached are removed and cleaned out. During the elution phase it is recommended to 
use a solvent that will elute the metabolites of interest at the lowest flow rate possible, so any 
interferences more strongly retained on the inside of the column are not also eluted (Qriouet 
et al., 2019). 
 
SPE is the most widely used sample preparation method given its quick process, high 
reproducibility rates and the ability to extract compounds that are generally difficult to 
extract. Disadvantages of SPE are its high cost and its effect on the environment due to the 
use of plastics. 
 
LLE is commonly used for any preparation involving aqueous and biological samples (El-
Beqqali and Abdel-Rehim, 2016; Højskov, Heickendorff and Møller, 2010). During sample 
preparation an aqueous sample containing the analyte and an immiscible organic solvent are 
mixed to transfer the analyte into the organic solvent (Ashri and Abdel-Rehim, 2011). This 
method has proven to give good recovery rates. There are some disadvantages of this 
procedure such as time consumption and a high environmental cost due to large amounts of 
toxic solvents being used. As well as this, LLE is not suitable for the extraction of multiple 
analytes with varying degrees of polarity from the same sample (Moein, El Beqqali and 
Abdel-Rehim, 2017). However, as a simple low-cost extraction procedure, it is still 
commonly used either as the sole extraction technique or a sample preparation precursor to 
SPE. 
 
1.20 Method Validation 
 
Method validation has a crucial role and is the most important step in regulatory affairs to 
ensure the quality of the applied method is sound, not only at the time of development but 
continuously after long periods of use. For the analytical method to be validated for road 
traffic toxicology, it must accurately detect and measure the benzodiazepines of study well 
within the range, legislated under Section 5a. Parameters for method validation are required 
to be in line with the requirements and recommendations  set out in the Forensic Science 
Regulator FSR-C-133 document and must include method accuracy (the closeness of the 
calculated value to the true value) and acceptance criteria, method precision (closeness of 
repeated measurements) [Coefficient of Variation (CV) or Relative Standard Deviation 
(RSD)] and method sensitivity (Limit of Detection, Upper and Lower Limits of 
Quantification); LOD is the lowest concentration of the analyte that can be reliably 
differentiated from background noise while LOQ is the lowest concentration that can be 
reliably quantified. Method selectivity is the techniques ability to identify the compound of 
interest in the presence of other similar components in the biological sample (such as other 
benzodiazepine drugs) and other related potential interferences. A further requirement for 
rigorous method validation is the quantification of matrix effects, these chiefly refer to ion 
suppression and enhancements. Matrix effects is defined as the interference in a signal due to 
impurities in the biological sample. In the case of blood samples this can be plasma proteins, 
minerals or vitamins that may elevate or suppress the ionisation signal.   Matrix effect studies 
which quantify the level of matrix effect can be quantified by using either post column 
infusion or post extraction spike, the former is a qualitative analysis that predicts where on 
the chromatographic run an interference may occur while the latter is a quantitative 
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assessment on the level of suppression/enhancement. Recovery of each drug and acceptance 
criteria. Stability of each drug (ensure that the drug of interest is not compromised throughout 
the analysis process). This includes stability pre-analysis and post analysis storage (including 
any freeze/thaw cycles if appropriate). Calibration method and acceptance criteria, where 
weighted curves are used for calibration the laboratory must be able to experimentally justify 
the weighting used. Robustness (effect of minor variations, for example variation in analyst, 





Currently there is a lack of methods that can reliably analyse a range of benzodiazepines. As 
a result, the development and validation of a method that can quantify benzodiazepines, 
namely diazepam, oxazepam, temazepam, clonazepam, lorazepam and flunitrazepam in a 
single run would with a short run time would be a benefit for casework laboratories. These 
benzodiazepines have been chosen as they have reliable reference materials and are amongst 
the most predominantly detected and commonly abused of this class of drugs in the UK. In 
addition to this, the aforementioned benzodiazepines are all stipulated in Section 5A of the 
road traffic act. 
• The criteria which the method will be validated will be in line with ISO 17025 
recommendation for method validation.  
• Method development will be carried out by doing scouting runs to find ions. 
• Validation experiments carried out will be accuracy, precision, linearity, reliability, 
repeatability, LOD, LOQ and specificity. 
• This research project will assess matrix effects, recovery rates as well as stability parameters.  
• Results shall be reported in units of micrograms per litre where applicable to facilitate 
























2 Materials and Methods 
 
2.1 Reagents and Chemicals 
The following reagents and chemicals were employed in this project; LCMS grade water 
(Fisher Scientific), Formic acid (Sigma Aldrich), LCMS grade acetonitrile (Fisher Scientific), 
Acetic Acid (Fisher Scientific), HPLC grade methanol (Fisher Scientific), HPLC grade 
methanol (Fisher Scientific), ethyl acetate (Fisher Scientific) , acetyl acetate (Fisher 
Scientific), distilled water. 
Cerilliant solutions: Diazepam 1.0mg/mL, Oxazepam 1.0mg/mL, Temazepam 1.0mg/mL, 
Lorazepam 1.0mg/mL, Clonazepam 1.0mg/mL and Flunitrazepam 1.0mg/mL; internal 
standards, Diazepam-D5 100μg/mL , Oxazepam-D5 μg/mL, Temazepam-D5 μg/mL, 
Lorazepam-D5 μg/mL, Clonazepam-D8 μg/mL, Flunitrazepam-D8 μg/mL. 
 
2.2 Reagent Preparation 
 
The following reagents were made and used for sample preparation and extraction. 
Internal standard (working solution (WS) E) 
To a 2.5mL volumetric flask add diazepam-D5 100μg/mL (100μL) , oxazepam-D5 μg/mL 
(50μL), temazepam-D5 μg/mL (125μL), lorazepam-D5 μg/mL (20μL), clonazepam-D8 
μg/mL (10μL), Flunitrazepam-D8 μg/mL (50μL) and then make up to 1mL using methanol. 
Table 3: Preparation of Internal standards (working solution E)  
Internal 
standard  
Added volume of internal 
standard (mL)  
Volume of Methanol made 
up to (mL)  
Final concentration 
(µg/L)  
Temazepam  2.5  5  500  
Oxazepam  1  5  200  
Lorazepam  0.4  5  80  
Flunitrazepam  1  5  200  
Diazepam  2  5  400  
Clonazepam  0.2  5  40  
 
Solution for calibrator (WSA) 
To a 5mL volumetric flask add diazepam 1.0mg/mL (50μL), oxazepam 1.0mg/mL (50μL), 
temazepam 1.0mg/mL (125μL), lorazepam 1.0mg/mL (20μL), clonazepam 1.0mg/mL (10μL) 
and flunitrazepam 1.0mg/mL (50μL). Make the volume up to 5mL using methanol. 
 
Table 4: Preparation of Drug analytes (working solution A)  
Analyte  Added volume of analyte (mL)  
Volume of Methanol made up 
to (mL)  
Final concentration 
(µg/L) 
Temazepam  125  5  25000  
Oxazepam  50  5  10000  
Lorazepam  20  5  4000  
Flunitrazepam  50  5  10000  
Diazepam  100  5  20000  
Clonazepam  10  5  2000  
 34 
 
Borate buffer (pH 9) 
Two solutions A and B made up. Solution A: to a beaker add boric acid (6.18g) and 
potassium chloride (7.46g) and then dissolve into 100mL milli-Q water. Solution B: dissolve 
sodium carbonate (10.6g) into 100mL milli-Q water. From solution A remove 63mL and 
from solution B remove 37mL and place into separate beaker. Stir through thoroughly. 
 
2.3 Preparation of calibration line and quality control samples 




2.4 Sample preparation and extraction 
 
Sample preparation 
Samples, calibrators, blanks and quality control (QC) standards had a starting volume of 1 mL 
of whole blood in 15mL conical centrifuge tubes. Internal standard (30 µL) from WSE was 
added to all samples, calibrators, quality controls and vortexed thoroughly for ≈1min. 
Following this WSA was used to add 10 µL, 20 µL, 30 µL, 40 µL, 50 µL, 60 µL, 15 µL, and 
35 µL to each separate conical centrifuge tube before being vortexed for ≈1min each. Borate 
buffer (145 µL) was then added to each tube before being vortexed for a further 5 mins. Ethyl 
acetate (1.5 mL) was added to each tube before centrifuging at 3500 rpm for 5 mins. Following 
this, the supernatant was removed and ≈1 mL was placed in a Agilent vial. The liquid was 
evaporated via use of nitrogen gas in a sample contactor at 40°C before adding 250 µL with 












































Cal 1 10µL A 30 µL E 200 100 250 20 40 100 
Cal 2 20µL A 30 µL E 400 200 500 40 80 200 
Cal 3 30µL A 30 µL E 600 300 750 60 120 300 
Cal 4 40µL A 30 µL E 800 400 1000 80 160 400 
Cal 5 50µL A 30 µL E 1000 500 1250 100 200 500 
Cal 6 60 µL A 30 µL E 1200 600 1500 120 240 600 
QC low 15µL A 30 µL E 300 150 375 30 30 150 
QC high 35µL A 30 µL E 700 350 875 80 80 350 
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2.5 Instrument and laboratory equipment 
 
LC; Agilent 1260 Infinity Binary Pump 
MS: Agilent Triple Quad LC/MS 6430 
Column measurements: Synergi 4 μm Fusion-RP 80 A LC Column 150x2mm 
15mL conical Centrifuge tubes from Fisher Scientific, utilised in sample preparation 
5mL LABCO vials 
Pipettes: VWR positive displacement pipette 1 -10 μl, VWR positive displacement pipette 10 
-100 μl, VWR positive displacement pipette 100 -1000 μl. 
 
2.6 Instrument parameters 
 
The parameters for ion source were: Positive electrospray, gas temperature at 350°C, gas 
flow at 12L/min, nebulizer 25 psi, capillary +4000V. EMV+ 400. 
The parameters for LC: Mobile phase A 1.0L water, 1mL 0.1% formic acid, 0.15g acetyle 
acetate. Mobile phase B 1mL 0.1% formic acid, 250mL acetonitrile. Temperature 20°C, stop 
time for LC pump 10.6 min, injection with needle wash (acetonitrile as wash solvent), 
injection volume 20µl, injection draw position -1.6mm, injection draw speed and eject speed 



































3.1 Development of an analyte library 
 
Post column infusion with a syringe pump at the speed of 5µL/min and MassHunter Optimizer 
software was used to construct the analyte database. The settings for the ion source were the 
same for all analytes, as described in the method section. All analytes were infused individually 
with the software settings as described in Table 6. All samples were made in 50:50 (mobile 
phase A, water 0.1% formic acid and mobile phase B, acetonitrile 0.1% formic acid mix) for 
infusion at a concentration of 100ng/mL. The optimiser software identifies the parent ion and 
its respective optimum fragmentation energy and collision energy for the as well as quantifier 
ion transitions (MRM). The results of all compounds precursor ions and product ions and 
energies are presented in Table 7. 
 
















3.2 LC Gradient Development 
The development of the LC separation method was based on literature research of methods that 
previously analysed benzodiazepines. The Phenomenex C18 Synergi Fusion (Reverse Phase) 
column was selected; this was chosen as it displayed good retention of polar analytes and is 
aqueous stable with TMS capping that ensure column durability and good peak resolution. The 
solvents used consisted of a Aqueous mobile phase A (water 0.1% formic acid) and an organic 
mobile phase B (acetonitrile 0.1% formic acid), with conditions for the isocratic gradient 
described in (Table 8). The gradient achieved adequate separation for the compounds, with the 
exception of the IS of Clonazepam and Flunitrazepam, to provide sufficient co-elution the run 
time was extended from 0.35 to 0.45mL/min.  The final optimised chromatography method is 













Table 7: Compounds and precursor ions and product ions. 
Analyte name 
 
Parent ion m/z 
 








Diazepam-D5 290.1 198.2  





Lorazepam-D4 325.1 297  





Oxazepam-D5 292.1 246.2  





Clonazepam-D4 320.1 274.2  





Temazepam-D5 306.1 260.3  





Flunitrazepam-D7 321.1 275.2  
 
 
3.3 Method Optimisation 
 
Following testing of different LC gradients, an optimal gradient was found. Optimisation of 
the method was then carried out to accomplish accurate identification and quantifications of 
all drugs in a single runtime. Ion source optimisation was achieved through testing of 
different flow rates and nebuliser pressures, both of which affected sensitivity. 
Reconstitution volume was set at a volume of 250µL in order to provide enough volume for 
injection and reinjection if required. The reconstitution liquid used was mobile phase B 
(acetonitrile, 0.1% formic acid), throughout the duration of the project as it attained the best 







Table 8: Original LC Gradient Elution Method Parameters 
Time (min) Mobile Phase A Mobile Phase B Flow rate 
(mL/min) 
Max pressure 
     (kPA) 
0.00 70 30 0.35 500 
1.00 70 30 0.35 500 
2.50 50 50 0.35 500 
6.00 50 50 0.35 500 
6.50 70 30 0.35 500 
8.00 70 30 0.35 500 
 
Table 9: Amended LC Gradient Elution Method Parameters 
Time (min) Mobile Phase A Mobile Phase B Flow rate 
(mL/min) 
Max pressure 
      (kPa) 
0.00 70 30 0.45 500 
1.00 70 30 0.45 500 
2.50 50 50 0.45 500 
6.00 50 50 0.45 500 
6.50 70 30 0.45 500 
8.00 70 30 0.45 500 
 
During the method development stages co-elution issues arose with clonazepam and 
flunitrazepam internal standard. Temperature, pressure and run-time parameters were 
changed to no affect. Following this the flow rate was amended from 0.35µl/min to 












3.4 Method Validation Plan 
Table 10: Validation table (Forensic Science Regulator FSR-C-133, 2016) 
Criteria Experiments to be conducted Required 
performance criteria 
Result 
Accuracy This will be assessed using the 
Quality Control (QC) results 
obtained from repeatability and 
reproducibility batches. All 
batches contain QC samples at 
two concentrations. A low and 
high concentration contained 
within the calibration curve. 
Accuracy will be assessed if 
the measured concentration is 
within 20% of the spiked 
concentration. 
Expecting that the 
measured 
concentration will be 
within 20% of the QC 
concentration. 
Pass for all 
analytes. 
Precision This will be assessed using the 
QC results obtained from 
repeatability and 
reproducibility batches. A 
minimum of 5 different 
extractions are assessed, each 
contains QC samples at 2 
concentrations (low and high). 
CV% value will be assessed on 
the five different extractions. 
The %CV is not 
expected to exceed 
10%. 





Linearity will be demonstrated 
by running a 6 point calibration 
curve, minimum 5 separate 
extractions to be assessed. 
It is expected that the 
R2 of the curves will be 
equal or greater than 
0.99 for all analytes 
 
Pass for all 
analytes 
LOD Blank matrix is spiked with 
analytes at 50% concentration 
of the LOQ and run alongside 
extracted QCs and calibrators.  
The LOD will be the 
lowest concentration 
at which the S/N ratio 
is greater or equal to 
3:1 and achieves 
identification criteria 
(retention time, mass 
spectral ion ratios 
based on calibration 
curve of the run) 
 
Pass for all 
analytes.   
LOQ The LOQ for the analytes will 
be the lowest calibrator. 
Accuracy will be assessed, and 
all ion ratios must be within 
20% of the target. 
It is expected that no 
significant difference 
between calculated 
value and expected 
value will be found. 
Signal to noise ratio 
will be above or equal 
to 10:1, identification 




time, mass spectral 
ion ratios based on 
calibration curve of 
the run) will be met.  
Specificity Drugs in question will be all 
analysed in separate samples to 
ascertain whether the method 
specifically picks up each 
separate drug. 
Drugs will be analysed in multi 
drug samples and in individual 
drug spiked samples. 
The method is 
expected to 
discriminate drugs in 
both sample types on 
the basis of retention 
time and ion ratios. 
There should be no 
cross identification of 
drugs in either single 
or multi drug samples. 
 
 
Pass for all 
analytes. 
Repeatability A sample will be extracted on 
two separate occasions and the 
concentrations measured and 
compared with each other. 
No significant 
difference is expected 
analytes to be found 
for the concentration 
the difference should 
not be 7.5% 




This will be assessed by 
preparing 3 separate exactions 
on 3 separate days by 3 separate 
analysts. Each batch will 
contain a calibration curve 
consisting of 6 points and QC`s 
at 2 different concentrations. 
The measured 
concentration for QC 
samples passes the 
accuracy criteria. 




Post extraction addition 
approach is used in which two 
sets of samples are compared. 
Set 1 consists of samples spiked 
with analytes and their internal 
standards in 1mL of LCMS 
grade methanol and afterwards 
reconstituted. 
Set 2 consists of samples spiked 
with analytes and their internal 
standards before the 
evaporation of the elution 




The ion suppression or 
enhancement will be 
established at low and 
high concentrations. 
The values should not 
exceed 25% however 
if the values exceed 
25% impact on LOD, 
LOQ. Bias is 
evaluated, all 3 values 
are suitable, pass the 
required criteria. 
 
All analytes have 
matrix effect 
higher than 25%, 
however the 
LOQs, bias is not 
affected for any 
of the analytes. 
Recovery (RE) Pre spiked and neat sample sets 
are compared. Set 1(A) consists 
of samples spiked with analytes 
and their internal standards in 
RE%=C/Ax100 
 
Recovery will be 
established at low and 
high concentrations. It 
All analytes have 
a recovery above 




1mL of LCMS grade methanol 
and afterwards reconstituted. 
Set 3 (C) consist of blank 
blood samples spiked with 
analytes and their internal 
standards followed by 
extraction procedure. 
is expected that the 
recovery is above 80% 
or if not it does not 





the LOQs, bias is 
not affected for 
any of the 
analytes. 
Stability Stability is tested by analysing 
the same blood sample, spiked 
with analytes, on two different 
occasions, on day one and then 
after a week. 
 
Stability of extracted samples is 
tested by extracting samples 
and keeping them in the 
refrigerator/freezer for two 
weeks. 
 
The blood sample 
concentration should 
be similar (not 
different by more than 
20%) on both days 
when analysed. 
 
The extracted samples 
after being kept in the 
refrigerator/freezer 
should still pass bias 
and linearity criteria. 
 
































3.5 Method Validation Results 
Accuracy 
Accuracy is the closeness of the calculated value to the true value. The accuracy is determined 
as a percentage by comparing the calculated concentration to the expected concentration. All 
benzodiazepines were expected to be within ±20% of the target concentration. Five runs are 
examined with 2 duplicates of low and high concentration QCs. The accuracy results can be 
viewed in Tables 11-12. The accuracy of analytes, which had their respective deuterated 
internal standards was in the range of 20%. The method can quantify all analytes with an 
acceptable accuracy. 
 
Table 11: Low QC values for all six benzodiazepines 
Analyte Low QC Value Target 
Concentration 
(µg/L) 
Accuracy (%)  
Diazepam 331.80 300 110.60 Pass 
Oxazepam 166.88 150 111.25 Pass 
Temazepam 417.53 375 111.34 Pass 
Clonazepam 34.41 30 114.71 Pass 
Lorazepam 66.07 60 110.11 Pass 




Table 12: High QC values for all six benzodiazepines 
Analyte High QC Value Target 
Concentration 
(µg/L) 
Accuracy (%)  
Diazepam 760.57 700 108.65 Pass 
Oxazepam 379.12 350 108.32 Pass 
Temazepam 938.55 875 107.26 Pass 
Clonazepam 69.81 70 99.73 Pass 
Lorazepam 166.44 140 118.88 Pass 
Flunitrazepam 394.76 350 112.78 Pass 
 

















Precision of the method shows the closeness of repeated measurements, the agreement 
between results when the method is used repeatedly. Precision was assessed using the QC 
results obtained from repeatability and reproducibility batches. 5 different extractions were 
assessed, each contains QC samples at 2 concentrations (low and high). CV% value was 
assessed on the five different extractions. The between day precision is calculated by looking 
at all values for the QC (n=10), finding the standard deviation for them, diving it by the mean 
of QC (n=10) and multiplying by 100. The %CV value was below 20% for all analytes. 
 
Table 13: %CV for QC1 and QC2 between days for all six benzodiazepines 
 
Analyte %CV QC1 Between days %CV QC2 Between days 
Diazepam 3.89 1.62 
Oxazepam 4.81 0.85 
Temazepam 5.34 1.10 
Clonazepam 2.45 3.79 
Lorazepam 6.79 2.63 





Linearity is a theoretical mathematical model utilised to highlight the relationship between 
the response of an analyte and the concentration. This was tested by running a six-point 
calibration curve on 5 separate days with 5 separate extractions. A weighing factor of 1/x was 
utilised for all analytes. The method successfully passed the criteria achieving greater than 
0.99 for R2 for all analytes.  
 
Table 14: The linearity is displayed in table 14.  
 
Analyte name Linearity 
R2day 1 
Linearity 
R2 day 2 
Linearity 
R2 day 3 
Linearity 
R2 day 4 
Linearity 
R2 day 5 
Diazepam 0.9988 0.9921 0.9947 0.9940 0.9980 
Oxazepam 0.9991 0.9901 0.9953 0.9955 0.9987 
Temazepam 0.9981 0.9904 0.9952 0.9950 0.9969 
Clonazepam 0.9936 0.9949 0.9936 0.9960 0.9929 
Lorazepam 0.9969 0.9910 0.9934 0.9945 0.9939 
























LOD is the lowest concentration of an analyte that can reliably be distinguished from 
background noise. Samples for LOD testing were prepared at half the concentration of 
Calibrator 1 (LOQ) for all analytes. Samples were then analysed and added to a calibration 
curve before analysing the signal to noise ratio, the ion ratio and retention time. Although 
quantitative values were generated, the values fall outside the calibration curve and therefore 
accuracy of the quantitation cannot be assured. 
 
Table 15: LOD result summary. Three LODs were analysed on different days 
 







101.2862 101.28 838.981 Pass 3.986 
100.1056 100.10 1224.878 Pass 4.005 
100.9832 100.98 948.531 Pass 3.991 
Oxazepam 
52.4442 104.88 177.217 Pass 2.611 
51.1246 
102.24 
          
379.953 
Pass 2.632 
52.2850 104.57 336.037 Pass 2.630 
Temazepam 
132.5015 106.00 7500.841 Pass 3.550 
122.1375 97.71 2601.956 Pass 3.550 
132.2375 105.79 5091.713 Pass 3.558 
         Clonazepam  
10.9114 109.11 38.224 Pass 3.973 
9.4758 94.75 33.493 Pass 3.286 
10.7889 107.88 151.267 Pass 3.478 
Lorazepam 
20.7126 103.56 251.821 Pass 2.875 
20.8786 104.39 39.058 Pass 2.865 
21.4784 107.39 403.751 Pass 2.875 
Flunitrazepam  
54.3658 108.73 1378.516 Pass  3.675 
48.8126 97.62 900.210 Pass  3.632 
54.5560 109.10 3000.152 Pass  3.824 













LOQ is the lowest concentration that can be reliably quantitated and in the scope of this 
project, the lowest calibrator in each run was considered was assigned to be the LOQ. In all 
cases ion ratio was assessed to be within 20% of target and signal to noise ratio was above 
3:1. The results are detailed in Table 16: 
 
Table 16: LOQ result summary. Three LOQs were analysed on different days 





     199.9922        100.00 199.9922 Pass 
     205.8465        102.92 1386.537 Pass 
      207.4889        103.74 1555.468 Pass 
Oxazepam 
100.3690 100.37 661.625 Pass 
      106.1678        106.16 483.797 Pass 
      102.0265        102.02 1053.291 Pass 
Temazepam 
235.3445 94.14 2981.174 Pass 
260.9773 104.39 5615.713 Pass 
      262.6250        105.05 1815.365 Pass 
Clonazepam 
21.4754 107.38 11.141 Pass 
19.6973 98.48 204.528 Pass 
22.2647 111.32     408.901 Pass 
Lorazepam 
37.0240 92.56 100.247 Pass 
16.8768 84.38 321.066 Pass 
20.2546 101.27 342.845 Pass 
Flunitrazepam 
98.6815 98.68 2625.596 Pass  
109.3795 109.37 1610.146 Pass 










Specificity is the capacity of a method to detect the target analyte without detecting other 
non-target analytes. Samples were spiked with the analytes in separate samples and results 
were compared to other benzodiazepines to see differentiation.  
                                   
 























































Figure 18. Representative chromatograms showing ion ratios for 


















Figure 19. Representative chromatograms showing ion ratios for 





























Figure 20. Representative chromatograms showing ion ratios for 





























Figure 21. Representative chromatograms showing ion ratios for 





















Figure 22. Representative chromatograms showing ion ratios for 

































Figure 23. Representative chromatograms showing ion ratios for 





Repeatability was tested to investigate how effectively the method operated when testing the 
same samples on different days and how close the results were grouped together. Known 
concentrations of the samples were spiked at Cal 3 and extracted and then preparation of 
calibration curve and QC’s on the following days 25th July 2020 and then 28th July 2020. All 
analytes were expected not to differ by more than 10%. the results can be seen in table 18. 
 
                   Table 18: Repeatability sample values on two different days of analysis 
 










Diazepam 615.7126 598.7650 2.75% 
Oxazepam 307.2864 301.4842 1.88% 
Temazepam 752.9748 743.6387 1.24% 
Clonazepam 64.0456 59.8750 6.51% 
Lorazepam 127.5014 117.0398 8.21% 




Reproducibility was assessed by carrying out separate extractions by more than one analyst 
on separate days within the same laboratory. Three different analysts extracted calibration 
curves and QC.   
 
 
Table 19: Results for reproducibility experiments carried out by three different analysts 
 












Diazepam 0.9959 317.1743 105.72 710.1832 101.35 
Oxazepam 0.9955 158.3692 105.57 354.3216 101.23 
Temazepam 0.9950 401.1996 106.98 882.7542 100.88 
Clonazepam 0.9960 34.7680 115.89 75.6470 108.06 
Lorazepam 0.9945 60.8565 101.42 148.9203 106.37 
Flunitrazepam 0.9940 165.9730 103.67 358.3360 102.38 
Analyst 
2 
Diazepam 0.9994 296.2797 98.760 711.3950 101.62 
Oxazepam 0.9992 141.4143 94.270 356.7039 101.91 
Temazepam 0.9991 356.7946 101.94 870.3755 99.47 
Clonazepam 0.9945 29.8724 99.574 71.5555 102.22 
Lorazepam 0.9920 51.9544 86.590 142.8324 102.02 
Flunitrazepam  0.9993 150.6073 100.40 357.8981 107.39 




Oxazepam 0.9953 158.7116 105.80 355.2901 101.51 
Temazepam 0.9952 401.2165 106.99 882.1594 100.81 
Clonazepam 0.9936 33.8957 112.98 74.5301 106.47 
Lorazepam 0.9934 62.1495 103.58 148.5742 106.09 





Recovery is measured by comparing extracted samples to unextracted controls as a 
percentage and calculated by comparing analyte ion peak areas with the mathematical 
formula B/A x 100. An unextracted set of low, medium and high calibrators were compared 
with that of an extracted set in order to determine the amount of analyte recovered from the 
matrix. This is demonstrated in tables 20–25 showing percentage recovery for all six 
benzodiazepines. Recovery for all analytes is above 45%. The average recovery of the six 
benzodiazepines in this method is 56.72%. The sensitivity and LOQs for all analytes passed 
the required criteria of the method. 
 













Cal 1 1111718 518686 46.65 48.48 
Cal 3 3773493 1911544 50.65 

















Cal 1 212294 118716 55.92 49.39 
Cal 3 736334 345635 46.93 
Cal 5 1320903 598541 45.31 
 
 













Cal 1 568068 385961 67.94 55.84 
Cal 3 1741739 892811 51.25 
Cal 5 2934300 1418118 48.32 
 
 














Cal 1 5500 3131 56.92 46.59 
Cal 3 18286 7388 40.40 
Cal 5 28989 12303 42.44 
 













Cal 1 21886 15328 70.03 54.08 
Cal 3 79698 35801 44.92 
Cal 5 129130 61060 47.28 
 
 













Cal 1 34942 31240 89.40 85.96 
Cal 3 107610 90182 83.80 





























Matrix effect  
 
Matrix effects is the interference in a signal due to impurities in the biological sample. A 
quantitative technique is utilised to analyse matrix effect, also known as ion suppression or 
enhancement. An unextracted set of triplicates of low, medium and high calibrators were 
compared to that of a post extraction spiked set of triplicates to determine the effects of 
interfering compounds in the matrix other than the analytes in question. This is then 
compared and contrasted with the mathematical formula (C/A x 100)-100. Tables 26–31 
demonstrate ion enhancement (+ME value) or suppression (-ME value) for each analyte in 
the blood/benzodiazepine matrix. Overall, all analytes experienced ion suppression. Our 
results suggest that this method has an ion suppression present in all 6 benzodiazepines. The 
average ion suppression across all analytes was -48.43%. This has not affected the sensitivity 









area (A)  
Post spiked 










Cal 1 1111718 626562 -43.45 -48.75 
Cal 3 3773493 2064813 -45.28 
Cal 5 6224236 3644348 -41.44 
 
 





area (A)  
Post spiked 
peak area (C)  
Matrix effect 
percentage 






Cal 1 212294 105248 -50.42 -48.75 
Cal 3 736334 373979 -49.21 









area (A)  
Post spiked 
peak area (C)  
Matrix effect 
percentage 






Cal 1 568068 281107 -50.51 -46.88 
Cal 3 1741739 913195 -47.56 











area (A)  
Post spiked 
peak area (C)  
Matrix effect 
percentage 






Cal 1 5500 2215 -59.72 -48.15 
Cal 3 18286 7706 -57.85 
Cal 5 28989 15715 -45.78 
 
 





area (A)  
Post spiked 
peak area (C)  
Matrix effect 
percentage 






Cal 1 21886 10403 -52.46 -49.92 
Cal 3 79698 37380 -53.09 
Cal 5 129130 72053 -44.20 
 
 





area (A)  
Post spiked 
peak area (C)  
Matrix effect 
percentage 






Cal 1 24942 29017 -16.95 -48.15 
Cal 3 107610 10058 -90.65 


























The stability of samples was tested by analysing three different storage conditions and then 
compared to extraction concentrations detected on the same day. Storage was tested without 
any refrigeration and being left out at room temperature for a week. Second, testing was done 
on samples which had been kept in a refrigerator for a week as well as samples stored in a 
freezer for a week before being thawed and then analysed. Our results show good stability in 
all storage conditions tested with all the analytes being within 20% of target concentration. 
 
 










Diazepam Same day 
Extraction 
QC 1 300 317.6719 105.89 
QC 1 
Duplicate 
300 322.2032 107.40 
QC 2 700 692.3871 98.91 
QC 2 
Duplicate 
700 698.0715 99.72 





QC 1 300 317.8975 105.96 
QC 1 
Duplicate 
300 321.7242 107.24 
QC 2 700 683.9212 97.70 
QC 2 
Duplicate 
700 695.9866 99.42 




QC 1 300 325.8018 108.60 
QC 1 
Duplicate 
300 323.7268 107.90 
QC 2 700 694.4567 99.20 
QC 2 
Duplicate 
700 691.6591 98.80 




QC 1 300 329.7309 109.91 
QC 1 
Duplicate 
300 324.3609 108.12 
QC 2 700 696.6868 99.52 
QC 2 
Duplicate 
700 709.9952 101.42 
QC Mid 600 528.1242 88.02 
Oxazepam Same day 
Extraction 
QC 1 150 154.9266 103.28 
QC 1 
Duplicate 
150 162.1916 108.12 
QC 2 350 351.8320 100.52 
QC 2 
Duplicate 
350 363.1384 103.75 






QC 1 150 156.4390 104.29 
QC 1 
Duplicate 
150 158.7860 105.85 
QC 2 350 352.8720 100.82 
QC 2 
Duplicate 
350 350.4305 100.12 




QC 1 150 160.2048 106.80 
QC 1 
Duplicate 
150 158.6292 105.75 
QC 2 350 344.1014 98.31 
QC 2 
Duplicate 
350 357.3620 102.10 




QC 1 150 162.3410 108.22 
QC 1 
Duplicate 
150 159.7793 106.51 
QC 2 350 347.5310 99.29 
QC 2 
Duplicate 
350 356.2248 101.77 
QC Mid 300 264.9128 88.30 
Temazepam Same day 
Extraction 
QC 1 375 396.8175 105.81 
QC 1 
Duplicate 
375 395.9059 105.57 
QC 2 875 841.4997 96.17 
QC 2 
Duplicate 
875 866.1335 98.98 





QC 1 375 397.4713 105.99 
QC 1 
Duplicate 
375 398.8590 106.36 
QC 2 875 849.2170 97.05 
QC 2 
Duplicate 
875 867.4366 99.13 




QC 1 375 397.2482 105.93 
QC 1 
Duplicate 
375 397.5186 106.00 
QC 2 875 852.8401 97.46 
QC 2 
Duplicate 
875 857.6100 98.01 




QC 1 375 399.3173 106.48 
QC 1 
Duplicate 
375 396.8619 105.82 
QC 2 875 846.0722 96.69 
QC 2 
Duplicate 
875 883.0615 100.92 
QC Mid 750 651.5089 86.86 
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Clonazepam Same day 
Extraction 
QC 1 30 33.0078 110.02 
QC 1 
Duplicate 
30 32.2289 107.42 
QC 2 70 71.7408 102.48 
QC 2 
Duplicate 
70 74.7768 106.82 





QC 1 30 32.3361 107.78 
QC 1 
Duplicate 
30 31.5375 105.12 
QC 2 70 69.8852 99.83 
QC 2 
Duplicate 
70 71.2684 101.81 




QC 1 30 34.2808 114.26 
QC 1 
Duplicate 
30 33.5208 111.73 
QC 2 70 68.6232 98.03 
QC 2 
Duplicate 
70 73.3859 104.83 




QC 1 30 31.9713 106.57 
QC 1 
Duplicate 
30 33.1376 110.45 
QC 2 70 68.8668 98.38 
QC 2 
Duplicate 
70 70.2148 100.30 
QC Mid 60 55.9665 93.27 
Lorazepam Same day 
Extraction 
QC 1 60 70.0735 116.78 
QC 1 
Duplicate 
60 69.6753 116.12 
QC 2 140 145.0638 103.61 
QC 2 
Duplicate 
140 148.3126 105.93 





QC 1 60 67.3974 112.32 
QC 1 
Duplicate 
60 65.0422 108.40 
QC 2 140 139.9475 99.96 
QC 2 
Duplicate 
140 151.9030 108.50 




QC 1 60 65.9516 109.91 
QC 1 
Duplicate 
60 68.2853 113.80 
QC 2 140 138.1092 98.64 
QC 2 
Duplicate 
140 140.2633 100.18 





QC 1 60 68.9484 114.91 
QC 1 
Duplicate 
60 63.2523 105.42 
QC 2 140 138.8051 99.14 
QC 2 
Duplicate 
140 140.2633 100.18 
QC Mid 120 107.6931 89.74 
Flunitrazepam Same day 
Extraction 
QC 1 150 155.2555 103.50 
QC 1 
Duplicate 
150 158.4345 105.62 
QC 2 350 334.0062 95.43 
QC 2 
Duplicate 
350 351.1647 100.33 





QC 1 150 158.3729 105.58 
QC 1 
Duplicate 
150 160.9795 107.31 
QC 2 350 347.4074 99.25 
QC 2 
Duplicate 
350 355.8647 101.67 




QC 1 150 160.7179 107.14 
QC 1 
Duplicate 
150 162.4765 108.31 
QC 2 350 345.7210 98.77 
QC 2 
Duplicate 
350 354.6792 101.33 




QC 1 150 163.6993 109.13 
QC 1 
Duplicate 
150 158.5633 105.70 
QC 2 350 342.6982 97.91 
QC 2 
Duplicate 
350 353.4756 100.99 



















A method that could effectively detect and quantify six benzodiazepine analytes was 
developed. After method development phases of the project, the analytical technique was 
subject to validation procedures to ensure the reliability, effectiveness and general 
applicability of the method for casework purposes. This method was successfully validated 
for all six benzodiazepines included in Section 5A of the Road Traffic Act. 
 
Pre-method development literature research was carried out in order to identify the required 
ion transitions for the selected benzodiazepines. An array of previous studies researching 
benzodiazepines have utilised the same ion fragmentation pathways as the ones chosen in this 
project. The sample preparation, extraction and separation technique were based on 
methodology described by Simonsen et el., however, during the method development stages, 
modifications were made to improve recovery and efficiency.  
 
Following the successful method development for the column where scouting runs and 
optimisation of the gradient was carried out to ensure that there was no co-elution of analytes; 
the validation procedure was started. During the method development stages co-elution 
occurred between flunitrazepam and clonazepam. Modifications were first made to 
temperature and pressure without resolving the issue. Following this flow rate was changed 
from 0.35µL/min to 0.45µL/min which rectified the problem and separated the occurrence of 
both drugs. The parameters tested for the quantitative method are as follows: accuracy (bias), 
precision, linearity (calibration model) repeatability, reproducibility, specificity, LOD (limit 
of detection), LOQ (limit of quantitation), matrix effects and recovery. The FSR-C-133 
document has been published by the Forensic Science regulator to establish requirements for, 
and a common approach to, the analysis and reporting of the concentrations of certain drugs 
in relation to offences under Section 5A of the Road Traffic Act 1988. This is with regard to 
but not limited to quality standards, analytical requirements as well as unit requirements.  The 
criteria for the method should fall in line with UKAS (United Kingdom Accreditation 
Service) guidelines for optimal practice in ISO 17025 accreditation. Preceding method 
validation experiments on aforementioned parameters, a validation plan was created which 
outlined the criteria to be met for each method specification. All experiments undergone were 
performed on whole blood. 
 
The data collected indicates that the validated method is a reliable and accurate method to be 
employed in forensic toxicology and in line with Section 5A of the road traffic act testing 
specifications. The accuracy of results for all six benzodiazepine analytes passed the 
validation criteria. This highlights the methods ability to efficiently quantitate results.  
 
One common characteristic found in studies done in relation to benzodiazepines is long 
duration of the method run times, typically 20-35 minutes. Smink et al., 2004, devised a LC-
MS method for the detection of the six benzodiazepines listed in this study, however, in 
comparison to this method which completes the analysis in less than 10 minutes, the method 
validated by Smink et al., 2004 required over 20 minutes to complete analyte quantification. 
From a casework perspective a longer run time is typically disadvantageous as it permits 
fewer sample analysis and longer instrument usage, thereby being less cost effective. The 
validated method in this research project is ideal for large volume testing of road traffic 
samples whereby the variety of benzodiazepines encountered is relatively narrow. A 2017 
study by Rooney et al., indicated that over 90% of benzodiazepines encountered in road 
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traffic toxicology consist of diazepam and its two primary metabolites oxazepam and 
temazepam. The inclusion of the aforementioned metabolites are vital to be included in the 
study due to its prevalence from not only diazepam metabolism but also from their prescribed 
usage in their own right. By contrast, this method would need analyte expansion for use in 
criminal or post-mortem cases as the more common drugs of abuse such as the (non) 
benzodiazepine drugs like zolpidem and zopiclone. This can be seen in the works of ElSohly 
et al., (2006) who successfully validated a method for the detection of 22 benzodiazepines. 
One disadvantage of detecting more benzodiazepines is the much longer run-times in excess 
of 25 minutes. 
 
Accuracy was assessed by measuring two QC’s high and low concentrations, this method 
successfully detected all concentrations to within 20% of the target. Results were as expected 
with all the drugs being within the ±20% concentration range. All drugs except lorazepam 
were within ±15%. Precision was tested using repeatability and precision batches to calculate 
percentage coefficient of variance. All drugs passed the ±10% threshold with the highest 
value being lorazepam QC 1, as was seen in accuracy, with a value of 6.79%. LOD and 
LOQ’s all passed their criteria in terms of accuracy, S/N ratio and ion ratios. The method was 
able to accurately detect the target analyte without interference from other non-target 
analytes. It should however be stated that the LOD and the LOQ for this method are both at 
comparatively high concentrations, this is in line with the requirements of the calibration 
curve to be within a close concentration of the fixed limits of Section 5a. This highlights why 
this method is specifically useful as a road traffic testing tool and would not be suitable for 
casework samples such as DFSA where sub ng/ml detection limits are required. 
 
Matrix affects the concentration of the analytes by causing interference in a signal due to 
impurities in the biological sample that may elevate or suppress the ionisation signal, it is a 
vital to ascertain the degree of this effect. This was done by preparing three sets of low, 
medium and high calibrators containing all analytes. Set A consisted of a non-extracted 
methanol solutions spiked with concentrations equivalent Calibrators 1, 3, and 5 and their 
respective internal standards before being evaporated and reconstituted with 250µl of mobile 
phase B. Set B was prepared using calibrators 1, 3, and 5 and extracted as per the protocol 
with 1ml of blank blood. Set C was prepared using calibrators 1, 3, and 5 in blank blood, 
however, the calibrators were spiked post- extraction. Matrix effects were calculated using 
ME%=C/Ax100 as described by Matuszewski et al. 2003. The mean matrix effect ion 
suppression detected for all analytes was -48.43%.   
 
A further parameter investigated was extraction efficiency, this was done by calculating the 
percentage recovery of the sample preparation. Recovery was calculated by RE%=B/Ax100 
(Matuszewski et al. 2003). The recovery percentages were all above 80% in the Simonsen et 
al. 2010 study, while in this research project, the recovery percentages were averaged 50.87% 
for all analytes except for flunitrazepam in which 85.96% was recovered. To account for this, 
a deuterated internal standard was used. This is because the ratio of ion responses between 
the analyte and its respective internal standard is not affected by the matrix effect 
(Matuszewski et al. 2003). Any future research may benefit from optimising the extraction 
procedure and yield a higher recovery percentage. Recovery percentage is a limitation of this 
method as other research methods had percentages on average greater than 60% (Smink et 
al., 2004, Quintela et al., 2006). However, as this method is typically detecting higher 
concentrations of benzodiazepines a lower percentage recovery is not likely to have affected 
it adversely. It may be that alterations in centrifugation and pH could increase percentage 
recovery to that described in the Simonsen et al study. In addition, future work would benefit 
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from research with other parameters tested. A study by Gunn et al, (2010) did not use a 
buffer during the extraction process to avoid matrix effects caused by buffering salts in MS. 
 
This developed and validated method was used to determine the effects of temperature on the 
stability of benzodiazepines in blood. This is critical in casework environments as samples 
may be stored incorrectly at police stations, laboratories or during transfer. This research 
investigated what degradation of each individual benzodiazepine occurs when stored in 
different conditions. The blood collected for sample analysis in drug cases, in the UK, are 
held in road traffic vials with preservatives of sodium fluoride and potassium oxalate as 
anticoagulants. Samples in this study were stored at room temperature, refrigerated and 
freezer conditions. All samples were within 20% of the expected concentration highlighting 
good stability. 
 
A method for the analysis of benzodiazepines in road traffic toxicology is required for the 
new law which came into force on the 2nd of March 2015, not only due to the high usage of 
these drugs in society but also due to risks posed when driving under the influence of 
benzodiazepines. All benzodiazepines can potentially cause impairment while driving by 
negatively impeding cognitive as well as psychomotor performance. This validated method 
can be utilised for reliable quantification of these analytes. 
 
The introduction of per se limits in 2015 has radically changed the landscape of road traffic 
toxicology in England and Wales. Critically there has been a significant increase in the 
number of samples coming into forensic toxicology labs to be analysed for driving under the 
influence of drugs. Following the introduction of per se limits, the Driver and Vehicle 
Licensing Agency (DVLA) showed an increase in drug driving convictions (Freedom of 
Information Request 5687 Drug Driving). In the first three quarters of 2014 (prior to 
introduction of per se limits) there were a total of 805 convictions involving drug driving. In 
the first three quarters of 2016 (following the introduction of fixed limits) there were a total 
of 7,800 convictions involving drug driving (Freedom of Information Request 4976 Drug 
Driving).While individual police agencies have also reported significant increases in drug 
driving arrests, South Yorkshire police recorded 456 drug driving arrests in 2015 compared to 
13 in 2014. During the period of March 2015 to January 2016 Cheshire police recorded 530 
arrests compared to 70 in 2014. The North Wales arrest rate for March 2014 until March 
2015 was 32 compared with 224 from March 2015 to March 2016 (Freedom of Information 
request 2016/238 Drug Driving). 
 
This increase in drug driving sample submission after the introduction of fixed limits has 
previously been seen in other European countries such as Norway, where the introduction 
of per se limits resulted in a 20% increase in number of DUID samples taken (Vindenes, V et 
al., 2014). While in Sweden a 10-fold increase was seen after the introduction of fixed limits 
(Jones A.W, 2005). However, at this moment in time the roadside screening procedure is only 
approved for cocaine and THC (Home Office of GB). A recent study by LGC (TIAFT 2019) 
indicated that cannabis and cocaine now account for over 85% of road traffic samples, this is 
a contrast to a 2017 (Rooney et al 2017) study which indicated that prior to the introduction 
of Section 5a benzodiazepines were the second most prevalent drug encountered after 
cannabis. Numerous studies have shown that there is a high reported usage of 
benzodiazepines in motorist in the UK and Ireland, it is unlikely that this trend has changed 
even if the detection methodology has (Rooney et al., 2016, Officer. J, 2016, Cosbey, S.H, 
1986, Fitzpatrick et al., 2006). 
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Due to the lack of road-side screening for the majority of drugs listed in section 5A, those 
impaired by drugs, will experience a time delay between incident and sampling. The average 
time until sampling was found to be 3.23 hours after incident in 2010-12. A strong correlation 
is evident between the sampling time and the final drug concentration detected (Hartman et 
al. 2016). Given the already high limits in place for benzodiazepines, significant 
improvements must be made in sampling time in order to achieve increased efficiency and 
convictions for driving while impaired. It should be noted that a significant number of 
benzodiazepines that are detected by forensic laboratories following the introduction of per se 
limits are the result of poly drug use, typically cannabis and cocaine users who have are also 
taking benzodiazepines. With the low limits set for cocaine and high limits for 
benzodiazepines, recreational drugged drivers are more likely to be over the limit for cocaine 
and under the limit for benzodiazepines. As a result, limits set in place for benzodiazepines 
should be reconsidered. 
 
Although the introduction of Section 5a has vastly improved the ability of police forces to 
achieve prosecution in drugged driving cases due to stronger evidence via means of drug 
concentration analysis, it does contain several regulations and limits that could be improved 
on. In particular there is serious consideration that the medicinal drug limits are not be fit for 
purpose. The limits for certain benzodiazepines such as temazepam and diazepam are in 
excess of concentrations that cause impairment. A 1997 study by Druid and Holmgren found 
blood concentrations ranging from 10-50µg/L in a group of 130 intoxicated drivers.  Another 
study found average flunitrazepam concentrations to be at 18µg/L (Jones et al., 2007). 
However, the limits set out in Section 5A are significantly higher at 300µg/L. A study by 
Thatcher et al., 2003 found 14 people arrested for erratic driving which displayed slow and 
slurred speech as well as poor coordination found blood concentrations of lorazepam ranging 
between 10-320µg/L (average, 70). Another study of 22 impaired drivers found average 
lorazepam blood concentration levels at 30µg/L. The limit set in section 5A of the road traffic 
act is set at 100µg/L. Another significant factor in is the expanded uncertainties stipulated in 
‘The Analysis and reporting of forensic specimens in relation to S5a Road Traffic Act’. This 
provision states all analytes in that are tested under Section 5a have an analytical uncertainty 
subtracted from their measured concentration, it is the result after this subtraction that is 
utilised for court. The uncertainty subtractions for benzodiazepines are as high as 20%. For 
temazepam a 20% subtraction is performed on all samples, thereby effectively making the 
temazepam limit 1200µg/L, a concentration in excess of those previously reported in 
impairment cases (Baselt, 2020). Given the high limits set for benzodiazepine drugs, Section 
5a, is not the most effective legislation for the drug drive prosecution of benzodiazepines. 
Instead a charge of impairment under Section 4 of the road traffic should be used. The latter 
of which is an impairment offence with drug concentration used alongside manner of driving 
and a field impairment test. Section 5A has outlined a new offence of driving, attempting to 
drive or being in charge of a motor vehicle on public roads if the concentration of a specified 
drug in blood is above the prescribed limits. This has been designed to mirror provisions and 
laws set out for alcohol. Used in conjunction with other legislation pertaining to driving while 
impaired may be more effective. 
 
In the scope of this project, the office for Forensic Science Regulator have specified the 
requirements, common approach, analysis and reporting of the concentrations of drugs in 
relation to offences under Section 5A Road Traffic Act. This guidance can be found in the 
document titled ‘The analysis and reporting of Forensic Specimens In relation to S5A Road 
Traffic Act 1988 FSR-C-133 Draft (2016)’ to aid analysis of samples. The use of limits 
guidance is stipulated in the document ‘Section 5A Road Traffic Act 1988 Use of limits FSR-
 68 
G-221 (2020)’, while the validation parameters and guidance can be found in ‘Validation 
FSR-G-201 (2020)’. The laboratory should comply with the guidance on forensic toxicology 
issued by the United Kingdom and Ireland association of Forensic Toxicologists. In order for 
accreditation for Forensic service providers (FSP’s) for the analysis of drugs in relation to 
Section 5a of the Road Traffic Act, a minimum standard of validation must be met for all 
methods which comply with quality standards as outlined by ISO 17025. The analysis of 
blood samples shall be specifically listed in the scope of accreditation. It shall comply with 
the codes of practice and conduct (Ibrahim, 2017). The guidance provided for the validation 
indicates that prior to method validation and analysis of sample, the LC-MS shall be 
calibrated using a multi-point calibration curve (a minimum of a 5 point calibration curve 
with 2 QCs) and the acceptance criteria for the calibration correlation coefficient should be 
equal to or greater than 0.99. it is also stated that isotopically labelled deuterated standards 
should be used for analytes. In addition, an appropriate system suitability check must be 
determined for the parameters of mass spectrometer tuning, mass calibration, sensitivity 
(peak of the low calibration standard or signal to noise ratio), chromatography (peak 
asymmetry, peak resolution, retention time stability). Following this, for method validation to 
be achieved, precision and recovery shall be established for each drug in whole blood matrix. 
Recovery estimates relevant to the whole blood matrix and drugs under the investigation shall 
be determined by the use of spiking experiments. Precision should be estimated using 
analysis of variance to give a total error of standard deviation. Whole blood matrix must also 
be used for estimating a Limit of Detection (LOD) and this must be done for each individual 





This project successfully produced a validated method for the detection of six 
benzodiazepines in whole blood in line with the legislative criteria of Section 5a of the Road 
Traffic Act. It has been validated for diazepam, oxazepam, temazepam, clonazepam, 
lorazepam and flunitrazepam. Low as well as high concentration benzodiazepines can be 
measured simultaneously, with low detection limits, low limits of quantitation and fulfils 
satisfactory validation parameters. Recovery was tested and all analytes had a recovery of 
greater than 45%. Assessing matrix effects indicated that average ion suppression was -
48.43% for all analytes. Stability was assessed and all analytes passed the validation criteria. 
This method can reliably be used for the analysis of casework samples in line with the per se 
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